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Macrophages are acutely sensitive to changes within their environment 
and can readily develop into a variety of activation states important for both the 
progression and resolution of inflammation.  In response to immunological 
threats, macrophages must be able to effectively clear infections without 
sacrificing the integrity of the affected tissue.  Thus, these cells must successfully 
balance their activation responses in order to preserve tissue function and the 
overall health of the host. The failure to properly regulate macrophage activation 
responses often manifests in the clinic in a variety of disease scenarios including 
sepsis, chronic inflammatory disorders, and cutaneous Leishmaniasis. While 
many factors that drive the initiation of macrophage activation are known, it 
remains unclear what governs the transition to an immunosuppressive state.  
This study reveals that macrophages can control their own activation 
status through the coordination between the ecto-ATPase, CD39, and the 
adenosine 2a and 2b receptors (A2Rs).  The first part of this work shows that 
soon after toll-like receptor (TLR) stimulation, macrophages secrete and convert 
  
ATP into immunosuppressive adenosine via CD39. Moreover, we show that 
CD39 on macrophages is necessary to induce regulatory macrophage 
development and prevent severe immunopathology in a mouse model of septic 
shock.  The next sets of data demonstrate that TLR activation also enhances 
A2bR expression, thus completing the CD39-initiated autoregulatory circuit to 
limit inflammatory macrophage responses.  The second part of this work 
demonstrates that the chronic inflammatory disease-asociated cytokine, IFNγ, 
prevents TLR-induced A2bR expression and consequently promotes the hyper-
production of inflammatory cytokines by macrophages thereby revealing a novel 
mechanism by which IFNγ maintains overactive macrophages.  The final chapter 
illustrates that while the A2bR is the dominant adenosine receptor mediating the 
inhibition of inflammatory cytokine production, A2aR signaling inhibits nitric oxide 
generation and that its expression may be hijacked by intracellular parasites to 
evade innate host defense mechanisms. 
Thus, this study demonstrates that inflammatory macrophage activation is 
inherently transient and that macrophages can reprogram themselves. These 
results culminate in the discovery of a novel immunomodulatory mechanism 
reliant on macrophage purinergic signaling and offer new targets and strategies 
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Macrophage Activation States 
 
On a daily basis, humans encounter myriad microorganisms, some of 
which can cause detrimental damage to the host if not cleared efficiently.  The 
innate component of the host immune system is responsible for reacting 
immediately to microbial intrusion.  Effective protection of the host from infectious 
disease requires immune cells that must be able to 1) quickly recognize 
modulations within their microenvironment and 2) proficiently alert neighboring 
cells of infection.  The innate immune cells present at the site of infection are 
responsible for initiating the host immune response to ultimately resolve the 
infection and return tissue to normal homeostatic conditions.  There are a 
number of mechanisms by which the innate immune system operates to provide 
the first line of defense against pathogens including: surface epithelia, 
complement activation, and phagocytosis by leukocytes at the site of infection. 
 Macrophages are present in virtually all tissues of the body and are 
among the first resident cells to encounter invading pathogens.  Circulating 
monocytes that emigrate from the bloodstream, develop into tissue-resident 
macrophages.  A major function of macrophages is to rid the tissue of dead cells 
and cellular debris via phagocytosis.  However, phagocytosis alone does not 
induce sufficient levls of intracellular signaling that result in macrophage 
activation 1. Macrophages are also potent cytokine producers and rapidly 
respond to changes in their microenvironment.  Thus, the stimuli present in their 
extracellular environment are responsible for mediating macrophage activation 
responses including: cytokine production, anti-microbial activity, and antigen 
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presentation. Macrophages have the unique ability to alter their function and 
phenotype depending on the stimuli they encounter in tissue.  
Inflammatory macrophages 
 
Toll-like receptor (TLR) stimulation by pathogen-associated molecules 
such as lipopolysaccharide (LPS) elicits a pro-inflammatory activation state in 
macrophages characterized by their secretion of high amounts of inflammatory 
cytokines including IL-12 and TNFα. Inflammatory macrophages are the 
prototypical macrophage that develops at the onset of bacterial infection, 
inflammatory insult, and tissue damage. 
Activation of natural killer (NK), iNKT cells, and Th1 cells leads to the 
release of the type II interferon, IFNγ.  There are a number of IFNγ responsive 
genes including: inducible nitric oxide synthase (iNOS), class II major 
histocompatibility complex II (MHCII) and CD40, thus IFNγ is a major cytokine 
that instructs naïve macrophage to become potent anti-microbial cells.  
Furthermore, IFNγ  primes macrophages to be hyper-sensitive to TLR activating 
stimuli and intensifies TLR-induced inflammation.  TLR signaling culminates in 
the activation of the nuclear transcription factor, NFκB, which induces the 
transcription of pro-inflammatory cytokines such as IL-12 and TNFα and further 
upregulates IFNγ-primed genes.  Thus, upon exposure to TLR ligands and IFNγ, 
macrophages elevate secretion of TNFα, IL-12 as well as reactive nitrogen 
species, which inhibit the growth of intracellular pathogens 2.  Such pro-
inflammatory mediators act to bias CD4+ T cells to become Th1 effectors that 
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respond by producing high levels of IFNγ, which in turn amplify inflammatory 
macrophage activation responses, further recruits cells to the site of infection, 
and aids in the clearance of infection 3.  
Regulatory Macrophages 
 
Regulatory macrophages were first identified by our laboratory as being 
responsive to immune complexes in the presence of LPS 4. The hallmark 
regulatory macrophages is their ability to secrete increased levels of the potent 
anti-inflammatory cytokine, IL-10 5. These cells produce high levels of IL-10, but 
little IL-12; making these macrophages distinct from inflammatory macrophages.  
In addition, regulatory macrophages upregulate genes, which are different from 
those induced by the combination of IFNγ and LPS.  We have recently shown 
that in addition to IL-10, regulatory macrophages preferentially express heparin-
binding epidermal growth factor-like growth factor (HB-EGF), sphingosine kinase 
(SphK1), and IL-33 6, 7. Since the initial discovery that immune complexes and 
LPS yields an anti-inflammatory activation state, other regulatory-inducing stimuli 
have emerged including prostaglandins (PGE2), apoptotic cells, cAMP, and IL-10 
itself.  Previous work demonstrated these stimuli enhanced ERK activation in 
macrophages, which subsequently led to the phosphorylation of histone H3 at 
regulatory macrophage-associated loci.  ERK-mediated chromatin remodeling 
was important for increased promoter access by LPS-induced Sp1 resulting in 
enhanced transcription of macrophage-derived immunomodulatory mediators 
including IL-10 and HB-EGF 8. Indeed, we previously demonstrated that treating 
macrophages with cAMP could promote the development of regulatory 
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macrophages via ERK activation 7.  Furthermore, regulatory macrophage-derived 
IL-10 is an important suppressor of inflammation and may also act to inhibit 
macrophage function and contribute to uncontrolled parasitic infection 9. 
Alternative Activation and Wound Healing Macrophages 
 
The Th2 cytokines, IL-4 and IL-13, polarize macrophages to assume a so-
called ‘alternative activation state’ 86-88.  This alternatively activated macrophage 
(AAM) nomenclature stems from observations that in response to the IL-4/IL-13, 
macrophages are not potent cytokine producers 86-88. Thus, this activation state 
represents a stark contrast to any other previously identified characterizations of 
macrophages. However, the AAM terminology assumes that all non-inflammatory 
macrophage states are the same.  Moreover, this simplistic classification was 
largely based on in vitro observations and thus undermines the spectrum of 
immunomodulatory macrophage phenotypes observed throughout the 
pathogenesis of a disease in vivo.  Alternatively activated macrophages uniquely 
express elevated levels of the mannose receptor, Fizz1, and Ym1, which permit 
the identification of IL-4/IL-13-induced activation 86-88. Thus, IL-4/IL-13 treatment 
yields a state of activation distinct from regulatory and inflammatory 
macrophages.  Interestingly, the major macrophage function induced by IL-4/IL-
13 in has been enabling a tissue-remodeling program in macrophages.  Both IL-4 
and IL-13 signal to activate STAT6, which can drive expression of arginase. 
Arginase uses L-arginine as a substrate to produce L-ornithine, which goes on to 
serve as a precursor for collagen, thereby contributing to the maintenance of the 
extracellular matrix and resolution of tissue damage 1.  Thus, we have recently 
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proposed that their wound healing function be used in referring to IL-4/IL-13 
treated macrophages; in order to adequately distinguish between various 
macrophage activation states refer these cells.  Moreover, it is known that the 
presence of arginase promotes the survival of intracellular pathogens by 
producing polyamines and thereby providing microorganisms with nutrients that 
they cannot produce de novo 41, 42, 43.  Arginase also competes with iNOS for 
available L-arginine present in tissue, which can lead to ineffective production of 
anti-microbial NO 10.  
Summary 
 
These activation states vary dramatically in regards to mode of activation, 
anti-microbial activity, cytokine production, and antigen presentation. 
Inflammatory macrophages (also known as M1) are potent cytokine producers 
that contribute to the Th1 and Th17 responses and eradication of pathogens.  In 
contrast, wound healing and regulatory macrophages (collectively referred to as 
M2) are more permissive to bacterial and parasitic infections and are associated 
with an anti-inflammatory Th2 response.  It is important to note, that despite 
distinct functional differences between these three activation states, there is 
considerable overlap-particularly with regard to the genetic landscape each 
activation state exhibits, Furthermore, these macrophage phenotypes may be 
rapidly reversible.  It is believed that the phenotypic changes that macrophages 
undergo play an important role in determining the outcome of immune 
responses.  It is believed that macrophages have the ability to alter their function 
and phenotype depending on the stimuli they encounter in tissue. Collectively, 
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the ability for macrophages to readily alter their activation status in response to 
their changing microenvironment is a property referred to as “macrophage 
plasticity”. Moreover, it is plausible that depending on the combination of and 
exposure kinetics of stimuli sensed, macrophages may exhibit hybrid activation 
states and thus expressing biomarkers associated with more than one of these 
most well-characterized activation states. Thus there may be a “spectrum of 
macrophage activation states” (Figure 1).  
 




Figure 1. A schematic representing the myriad macrophage activation states. IFNγ and 
pathogen-associated molecules such as LPS induce inflammatory macrophages (red), which are 
potent producers of TNFα, IL-12 and anti-microbial nitric oxide.  In contrast, regulatory 
macrophages secrete high levels of IL-10 and arise in response to TLR stimulation in the 
presence of immunosuppressive signals (blue). In response to IL-4/IL-13 macrophages that are 
pro-angiogenic and suceptible to infection develop (yelllow).  Although at least three distinct 
activation states have been identified, macrophages exhibit functional plasticity and hybrid 
activation states may exist as they transition in response to changes sensed in their tissue 
environment. (Color wheel adapted from Mosser, DM and Edwards, JP Nat. Immun. Reviews. 
2008). 14 
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Importantly, macrophages must act quickly and appropriately to clear an 
infection before it spreads to the rest of the body, but these cells are also tasked 
with the challenge of controlling inflammation and repair damaged tissue once 
the pathogen is eradicated.  Failure to properly balance between anti-microbial 
activity and tissue repair therefore may result in chronic infection or tissue 
damage. Therefore, it is believed that the phenotypic and functional changes 
macrophages undergo, play a vital role in determining the outcome of infectious 
diseases. Thus, the body’s immune system relies on the ability to maintain 
properly regulated macrophages in order to effectively tune its response to 
physiological threats and ultimately to maintain tissue homeostasis.  
 
 
 10   
 
Macrophage plasticity during disease  
 
* Macrophages are major cellular contributors to the homeostasis of the 
host.  They can both respond to infection to enhance immune responses, and 
conversely contribute to the repair of tissue in the aftermath of an immune 
response.   It has been appreciated for many decades that exposure of 
macrophages to bacterial products can induce a profound phenotypic change, 
resulting in the secretion of many inflammatory cytokines and mediators.   Under 
different circumstances, however, these same macrophages can produce anti-
inflammatory molecules, thus macrophages make important contributions to both 
the initiation and resolution of inflammation.  These dramatic changes in their 
physiology are vital to maintaining homeostasis and protecting the host from 
severe immunopathology.  A variety of inflammatory disease scenarios suggest 
that macrophages equally exhibit the capacity to uniquely alter their responses to 
changing tissue environments, an ability referred to as ‘functional plasticity’ 
(Figure 2).  Despite these observations, however there remains a considerable 
dearth of understanding about how this transition from pro- to anti-inflammatory 
activation occurs in macrophages. The inability to maintain the temporal 
reprogramming of macrophage responses is evident in a variety of inflammatory 
and infectious disease scenarios.  
  
                                            
* Paragraph adapted from: Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage 
inflammatory responses. J Leukoc Biol. Nov 2013;94(5):913-919. 11 
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Figure 2. Schematic representation of phenotypic markers of macrophages at different 
stages of disease. Upon insult to tissue, the initial macrophage activation state is characterized 
by the expression of biomarkers associated with inflammation.  At later stages of tissue injury or 
infection, macrophages switch to a regulatory activation state by expressing phenotypic markers 
that suppress inflammation and promote tissue repair. (Adapted from Cohen and Mosser, JLB, 
2013). 11 
 




* More than 200,000 people in the US annually die from sepsis 12, a 
multifaceted disease that exemplifies the importance of intact regulated 
macrophage inflammatory responses. The initial phase of sepsis manifests as a 
systemic inflammatory response syndrome (SIRS) that is triggered by 
inflammatory responses to toll-like receptor (TLR) agonists, such as bacterial 
lipopolysaccharides (LPS) 13.  The severe pathology associated with SIRS occurs 
in response to the hyper-production of macrophage-derived inflammatory 
cytokines including TNFα, IL-12, and IL-1β which coalesce in a ‘cytokine storm’ 
that can lead to tissue destruction, vascular damage, septic shock, multiple organ 
failure, and death 13.  Compellingly, individuals who survive the initial pro-
inflammatory response, display a compensatory anti-inflammatory response 
develops that is accompanied by the appearance of monocytes/macrophages 
exhibiting a regulatory phenotype 14, 15.  Thus, the pathogenesis of sepsis is a 
temporally regulated process initiated by hyper-inflammatory macrophage 
response followed by a state of profound immunosuppression. 
* In fact, sepsis represents one of clearest examples of macrophages 
transitioning from a highly inflammatory population of cells to a population with 
immunoregulatory properties.  This transition has been referred to as “endotoxin 
tolerance”, a term that incorrectly implies that macrophages become non-
responsive to re-stimulation by bacterial products.  This, of course, is not the 
                                            
* Paragraph adapted from: Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage 
inflammatory responses. J Leukoc Biol. Nov 2013;94(5):913-919. 11   
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case because these macrophages actually undergo a transcriptional 
reprogramming resulting in dramatic shifts, both up and down, in transcript levels. 
There are many in vitro and in vivo models of endotoxin tolerance, and many of 
these models produce macrophages with subtle differences in their physiology, 
leading to some confusion about the specifics of tolerance.    Perhaps the most 
straightforward illustration of this phenomenon comes from an analysis of human 
monocytes taken from post septic patients and stimulated ex vivo with LPS.  
These monocytes produce substantially lower amounts of inflammatory 
cytokines, such as TNFα and IL-6, and they increase their production of 
immunoregulatory molecules, including IL-1RA and IL-10 16.  It is thought that this 
modulation in cytokine production is necessary to protect the host from 
immunopathology associated with prolonged macrophage activation.  In fact, in 
an in vivo mouse model of endotoxin tolerance, pre-exposure of mice to low 
levels of LPS protected mice from lethal doses of endotoxin 17.  There have been 
many reports identifying different potential molecular mechanisms behind 
tolerance 16 and it is likely that multiple molecular mechanisms may be 
responsible for this transition to a regulatory phenotype.  Despite differences of 
opinion regarding the mechanisms behind tolerance, there is general consensus 
that this phenomenon is real and that it may actually predispose post-septic 
patients to subsequent infections.  Thus, a mechanism to spare the host of 
inflammatory tissue damage may present an opportunity that infectious microbes 
can exploit thereby highlighting the essential role for tightly regulated 
macrophage responses in order to fully protect the host. Moreover, it is believed 
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that the inability to effectively control inflammatory macrophage activation 
responses is what drives this severe immunopathology and elucidating the 
molecular mechanisms mediating the macrophage plasticity will likely expand the 
currently limited arsenal of effective treatments for sepsis patients.  
Chronic inflammatory diseases 
 
* Chronic diseases that are instigated by inflammation exemplify the 
importance of the temporal regulation of macrophage activation in response to 
tissue damage. The destruction of tissue can lead to the release danger 
associated molecular patterns (DAMPs) from dying cells and an alteration in the 
extracellular matrix.  Neighboring monocytes/macrophages interpret this debris 
as ‘danger’ leading to their production of inflammatory cytokines.  High levels of 
ATP and HMGB1 that usually reside within cells, are released by dying cells into 
the extracellular tissue milieu to enhance the recruitment of migrating monocytes 
and activate macrophages to release the pro-inflammatory cytokine IL-1β 18-20.  
These events trigger an initial pro-inflammatory phase that is required to recruit 
innate immune cells and develop inflammatory macrophages at the site of tissue 
damage/injury to help fight potential microbial infection. Inflammatory 
macrophages originally develop at sites of tissue damage to initiate the wound 
healing process by phagocytosing dead cells and tissue debris and participate in 
host defense against microbes that may occupy the wound site.  Thus, early 
injury-associated macrophages typically release chemokines, lipid mediators, 
                                            
* Paragraph adapted from: Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage 
inflammatory responses. J Leukoc Biol. Nov 2013;94(5):913-919. 11 
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and a number of inflammatory cytokines, including (but not limited to) TNFα, IL-
1β, and IL-12, 21, 22.  
However, there are a variety of pathologies that develop in response to 
uncontrolled macrophage responses.  Unlike acute inflammatory diseases such 
as sepsis in which there is a distinct phase of inflammation followed by a 
compensatory immunosuppressive phase, chronic inflammatory diseases persist 
and display macrophages that fail to regulate their activation status.  There is an 
expansive list of diseases that exhibit chronic inflammation including Alzheimer’s, 
atherosclerosis, obesity, arthritis and inflammatory bowel disease23-26.  Thus, 
regardless of the initiating insult, the innate immune responses remain in a state 
of profound hyper-activation. One explanation for this is the continuous presence 
of inflammatory-causing stimuli such as beta-amyloid, elevated levels of low-
density lipoprotein, or persistent low-grade infections.  For all these diseases, 
damage to the tissue is apparent, thus leading to the constant exposure of 
inflammatory danger signals to resident macrophages.  Interestingly, elevated 
levels of IFNγ has been observed in rheumatoid arthritis and lupus individuals, 
suggesting a pathogenic role for IFNγ 25, 26.  To date, the most common 
treatments for many chronic inflammatory diseases are anti-IFNγ/TNFα 
therapies, which do not actively regulate inflammation, but rather merely inhibit 
pro-inflammatory responses.  This strategy, thus commonly results in 
substantially enhanced susceptibility to infections, as IFNγ and TNFα are crucial 
in host defense.  Thus, the need to investigate alternative mechanisms by which 
inflammation is sustained is eminent.  
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* Conversely, fibrosis develops as a result of over-active wound healing 
responses.  In genetically manipulated mice that lack macrophages, wound 
healing and re-epithelialization are substantially delayed 27.  Such observations 
indicate that the ensuing regenerative phase of wound healing requires the 
transition of macrophages from an inflammatory to a wound-healing phenotype 
21.  Once the inflammatory environment has subsided due to the release of 
potent anti-inflammatory mediators including IL-10 and TGF-β, macrophages 
present in tissue can successfully participate in the regeneration of tissue by 
producing tissue growth factors and promote collagen synthesis.  IL-10 is 
particular important in coordinating tissue repair within damaged muscle.  
Although IL-10 makes important contributions to the later (regulatory) stages of 
muscle development, it is actually detrimental to the early (inflammatory) stages 
of muscle development 28, 29.   Thus, the blocking of late IL-10 production can 
interfere with muscle regeneration, just as the addition of exogenous IL-10 early 
in the muscle repair process can disrupt regeneration.  This differential response 
to IL-10 (early versus late) illustrates how carefully the macrophage transition 
from inflammatory to regulatory must be controlled, and how important this 
transition is to proper muscle development.   
* Moreover, the activation status of macrophages at all stages of 
inflammation and wound healing appears to be tightly regulated.  If the early 
inflammatory response does not transition to an immunoregulatory response, 
                                            
* Paragraph adapted from: Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage 
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then inflammatory immunopathology will result in sustained inflammation and 
cause further tissue damage.  If the later regenerative phase is not properly 
regulated, then the wound healing response will progress to an obstructive 
fibrotic response that is associated with the formation of scar tissue as well as 
helminthic worm infections 30, 31.  In addition, the magnitude of these responses 
must also be carefully controlled.  Too much early inflammation, for example by 
injecting granulocyte-macrophage colony stimulating factor (GM-CSF), can 
exacerbate joint swelling 32, whereas too much late immunoregulation, for 
example by ablating arginase (Arg1), can lead to fibrosis 33.  Therefore, 
macrophages must be able to regulate their activation responses to prevent 
detriment to their local tissue environment, suggesting that the functional 
plasticity of macrophages is vital to maintaining tissue homeostasis.  
Cutaneous Leishmaniasis 
 
Leishmania are flagellated trypanosomes that cause a disease that 
plagues 1-2 million individuals each year throughout the world 34.  There are 
several forms of the Leishmaniasis including: cutaneous, mucocutaneous and 
visceral, with cutaneous Leishmaniasis being the most prevalent form of the 
disease in humans.  Individuals infected with L. major typically produce ulcers at 
the site of infection.  In most cases the lesions slowly self-healing, but in immuno-
compromised individuals ulcers do not heal.  Such individuals often suffer from 
debilitating lesions at the infection site that arise when the body fails to clear 
parasites before repairing the infected tissue scars. Cutaneous Leishmaniasis is 
a vector-borne disease that is transmitted by the sand fly, Phlebotomus papatasi, 
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which lives in endemic areas to North and West Africa and the Middle East.  In 
these areas, individuals may develop up to hundreds of lesions that often lead to 
severe debilitation 34-36.  
 Female sand flies are hematophagous and require a blood meal once a 
week for egg development.  To initiate its blood meal, the P. papatasi insert its 
mouthparts deep into the skin, reaching below the epidermis into the dermis, 
where it can reach blood vessels.  As the sand fly feeds, it secretes saliva to 
facilitate probing and feeding, resulting in the development of a small hematoma 
at the bite site and also regurgitates components within its gut into the open 
wound 37.  It is at this point, that infected sand flies transmit L.major parasites into 
the mammalian host. The parasite continues to be transmitted when the sand fly 
acquires its next blood meal from an infected mammal. 
 The life cycle of the parasite is complex and begins after the sand fly 
acquires blood from an infected individual.  Metacyclic promastigotes represent 
the infectious stage during the L. major lifecycle because this is the form of the 
parasite that is transmitted from the sand fly into the mammalian blood stream 
(Figure 3). Promastigotes are efficiently opsonized by host serum factors 
including complement and reactive IgG and due to their high expression of 
complement and Fc receptors, their phagocytic capacity, and residence in 
virtually every tissue of the body, macrophages are the primary host cell infected 
by Leishmania spp. 35, 38, 39 
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Figure 3. L. major metacyclic promastigotes as seen with phase-contrast microscopy. 
Leishmaniasis is vector-borne infectious disease that is caused by Leishmania spp.  This image 
captures the morphology of these flagellated trypanasomes at the stage of their life-cycle when 
they are transmitted from the sand fly into the blood of a mammalian host.  L. major metacyclic 
promastigotes primarily infect macrophages where they differentiate into a non-flagellated 
amastigote form that thrives intracellularly and can establish severe lesions at the site of infection 
in susceptible hosts. Scale bar, 50mM. (Image taken by Cohen, HB and from Goncalves, R., 
Zhang, X., Cohen, H., Debrabant, A., and Mosser, DM. JEM. 2011). 40  
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The use of mouse strains has established our foundational understanding 
of the pathogenesis of this disease caused by L.major. Interestingly, regardless 
of genetic background, both resistant and susceptible strains produce elevated 
levels of IL-4 early in infection. Thus, at the onset of infection, macrophages 
exhibit an immunoregulatory activation status.  Additionally, increases in parasite 
burden in both susceptible and resistant mice are associated with the induction of 
arginase in macrophages, which generates polyamines that support parasite 
growth 41, 42.  Furthermore, arginase utilizes the same sustrate as iNOS, L-
arginine and can thus interfere with the ability to effectively thwart intracellular 
pathogens 43.  
While the initial wound healing response is common between mouse 
strains, the ultimate fate is determined at later stages of infection.  In susceptible 
strains, parasite-specific antibodies begin to rise in the serum and can opsonize 
extracellular parasites, thus enhancing infection.  Furthermore, IgG-opsonized 
parasites promote IL-10 secretion from macrophages, thus sustaining the Th2 
environment and enhanced resistance in IL-10-deficient mice evidences the 
importance of IL-10 production during infection 9. It is unclear how L. major 
inhibits classical macrophage function and evades the host innate immune 
response.  Moreover, the hyper-production of IL-10 has been associated with 
chronic cutaneous lesions in human patients 35, 44.  Susceptible strains, thus 
exhibit long-lasting Th2 responses rich in IL-4 and IL-10 that support parasite 
survival, infection-induced tissue damage, and the development of non-healing 
lesions at the site of infection. In contrast, resistant strains ultimately control the 
 
 21   
 
infection by eventually developing a Th1 cytokine environment, dominated by 
IFNγ and IL-12 35, 45.  Thus, macrophages isolated from infected resistant strains 
exhibit an activation state consistent with inflammatory macrophages and are 
able to adequately clear control the infection.  It is important to note that in 
resistant mice, the site of infection eventually heals thereby indicating that 
macrophages alter their physiology again to assume a homeostatic activation 
state.  Thus, susceptibility to L. major infection is positively associated with 
chronic immunoregulatory macrophage activation and the failure to transition to 
an inflammatory activation state.  
Summary 
 
Macrophages readily alter their physiology in response to changes sensed 
within their local extracellular milieu.  Because macrophages are central to the 
development of both the progression and resolution of inflammation, it is 
imperative that we work towards improving our understanding of how 
macrophage plasticity is regulated.   
In myriad inflammatory and infectious diseases, the clinical outcome is 
often dictated by the ability of macrophages to maintain their capacity to readily 
alter their physiology.  Failure to retain functional plasticity and regulation 
between activation states can consequently lead to chronic diseases that can 
result in either severe tissue destruction or enhanced susceptibility to infections.  
In each setting, exogenous factors such as apoptotic cells, prostaglandin 
derivatives, cytokines, and growth factors accumulate over time that promote the 
development of regulatory macrophages. Thus, the switch from inflammatory to 
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regulatory macrophages is believed to play an integral role in returning damaged 
tissue to homeostatic conditions thereby protecting the host from further 
detriment.  It is further believed that the inability to effectively control the kinetics 
of inflammatory macrophage activation responses is what drives severe 
immunopathology. Studying the intrinsic ability of macrophages to transition to a 
regulatory state may provide some clues about the temporal regulation of 
macrophage activation during these diseases.  
It is important to recall that a wound caused by either needle inoculation or 
sand fly bite initiates the infection, thus a wound healing response may naturally 
develop to repair the damaged tissue. Tissue-resident macrophages in the 
presence of infectious agents, however, must be properly educated by their local 
microenvironment to promote host defense rather than tissue remodeling.  While, 
the role of cytokines including IFNγ, IL-12, IL-4 and IL-10 in directing the course 
of these diseases is well-documented, the role of other factors present in tissue 
during infection remain elusive.  
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Purinergic signaling  
 
 Despite its simplistic structure, composed of the purinergic nucleoside, 
adenosine bonded to a trio of phosphate groups, adenosine triphosphate (ATP) 
is essential for virtually all aspects of cellular function.  The vital role of ATP 
within cells is very well established as many cellular mechanisms depend on ATP 
including receptor signaling, transcriptional activation and DNA synthesis.  For 
these reasons, ATP is the most abundant nucleotide in cells existing at relatively 
high concentrations of 1-5mM within cells 46.  
Paradoxically, many mammalian cells are equipped with a variety of 
receptors and ecto-enzymes that recognize extracellular ATP. Thus, ATP must 
gain access to the extracellular space in order to activate these membrane-
bound molecules. In response to infection and tissue injury, damaged cells alert 
the immune system of a physiological breach by releasing danger associated 
molecular patterns (DAMPs).  Over 1mM ATP is within mammalian cells and 
when they lose membrane integrity, they release their cellular contents thus 
releasing high levels of ATP into the extracellular space. Infiltrating and resident 
innate immune cells express the P2X7 receptor, a membrane bound ion channel 
that has low affinity for ATP.  Thus in the presence of 1-5mM ATP, the P2X7 
becomes activated causing an efflux of potassium and activation of the 
intracellular NOD-like receptor protein 3 (NLRP3)-inflammasome, which 
ultimately leads to the secretion of the pro-inflammatory cytokine IL-1β.  If cell 
death persists and extracellular ATP levels remain elevated, severe tissue 
destruction caused by an overactive inflammatory response can occur. 
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Importantly, levels of extracellular ATP within the millimolar range are thought to 
occur only under pathological conditions. Therefore, in order to protect the host 
from such detriment, the ability to control extracellular ATP availability is critical. 
Indeed, a complex catabolic and signaling cascade exists to regulate the 
bioavailability of extracellular ATP, collectively referred to as “the purinergic 
signaling system” (Figure 4). 
  
 
Figure 4. Components of the purinergic signaling system.  In response to injury or infection, 
extracellular ATP levels can increase. eATP may be released through pannexin channels (Panx1, 
green) from intact, activated cells as well. eATP is metabolized by ecto-enzymes including CD39 
(red) and CD73 (black) to generate extracellular adenosine.  There are four adenosine receptors 
that are all GPCRs and include the A2aR and A2bRs (light blue), which couple to the Gαs 
subunit, and the A1R and A3R (dark blue), which couple to the Gαi subunit.  Finally, extracelllular 
adenosine levels can be further regulated its conversion to inoside by ADA (gray).  High amounts 
of eATP (>1mM) are released from dying and dead cells as they lose membrane integrity and can 
stimulate the P2X7 receptor (yellow).  
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Mechanisms of ATP release 
 
With regard to the immune system, much attention has been directed 
toward the consequence of immune cells recognizing high levels of ATP 
passively released from damaged and dying cells in response to immunological 
threats.  However, under homeostatic conditions, many intact healthy cells are 
able to actively release low levels (<1mM) ATP into their surrounding 
microenvironment.   Decades before its role in inflammation was appreciated, the 
active release of low levels (<1mM) ATP was first observed in activated neurons. 
Moreover, similar levels of ATP released from healthy muscle cells and platelets 
were also observed.  That discovery first suggested the idea that intact, healthy 
cells could possess the ability to respond to external cues in the form of ATP 
release, and importantly, use secreted ATP as a form of cellular communication 
in both paracrine and autocrine manners.  
ATP release from intact cells was first shown to occur via vesicular 
transport to release vesicle-stored ATP into the cleft of neurochemical synapses. 
Some non-neuronal cell types such as platelets exhibit a similar vesicle-based 
ATP release mechanism, however other cells may release ATP via cell 
membrane channels composed of either connexin or pannexin molecules.  
Originally identified for their role in gap junctions between adjacent cells, 
connexin and pannexin channels on individual, non-adjoining cells can act as a 
pore that controls the release of cellular ATP into the extracellular space. The 
pannexin family consists of three members. Of particular interest is pannexin 1 
(PANX1), which is the most abundant pannexin protein expressed in immune 
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tissues.  Recently, it was demonstrated that activated red blood cells and human 
neutrophils release ATP via pannexin-1 and that pannexin-1 channels also 
facilitate the release of ATP from activated T cells in response to T cell receptor 
and CD28 co-stimulation.  Thus, pannexin-1 channels been identified as a 
common component of ATP release from intact immune cells.  It is important to 
note that in these conditions of immune cell activation mentioned above, the 
pannexin-dependent release of ATP resulted in the release of relatively low 
levels (nanomolar-micromolar) of ATP into the extracellular space.   
Notably, although the pro-inflammatory effects of high levels of 
extracellular ATP released as a consequence of cell death is well documented, 
these relatively low levels of ATP released by intact cells are below the 
documented threshold of ATP required to activate the P2X7 receptor, therefore it 
remains unclear the immunological role for the release of low levels of ATP.  
Because excessive levels of ATP can contribute to severe tissue damage and 
inflammation, the immune system must be equipped with the ability to properly 
respond to and regulate the availability of secreted ATP in order to effectively 
support tissue homeostasis and overall health of the host. 
Extracellular ATP metabolism 
 
Ecto-enzymes are enzymes localized to the plasma membrane, in which 
their active site faces the extracellular space.  Four families of ectonucleotidases, 
which are capable of hydrolyzing extracellular ATP, have been identified in 
mammalian cells. Ectonucleoside triphosphate diphosphohydrolases 
(ENTPDases) have affinity for both extracellular tri- and diphosphates (ATP and 
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ADP) and can hydrolyze both to generate AMP and inorganic phosphate. This 
gene family is comprised of seven isoforms (ENTPD1-6,8), with ENTPD1-3 and 
ENTPD8 being extracellularly expressed. The first ENTPDase identified, and the 
best studied is ENTPD1, CD39 was originally cloned and sequenced as a B cell 
activation marker with unknown function in the mid-1990s 62, 63.   At the same 
time, a group of studies were performed that elucidated the function of CD39.  
First, soluble ATP diphosphohydrolyase (apyrase) from potato tubers was 
purified, cloned and found to have high sequence similarity to human CD39.  
Second, a dominant vascular ectonucleotidase was identified to possess potent 
thromboregulatory activity was cloned and found to be identical to CD39 as well. 
Since then, the role of CD39 in vascular and platelet biology has been 
extensively studied. The protein topology of CD39 reveals that the majority of the 
protein exists as a large extracellular catalytic domain flanked by two 
transmembrane domains and short cytoplasmic tails 62, 63.  Although, no direct 
intracellular signaling capability has been shown for CD39, it is believed to affect 
physiological conditions entirely by its ability to rapidly control bioavailability of 
extracellular ATP/ADP. 
More recently, with the development of CD39-deficient mice and CD39-
specific pharmacological inhibitors, the immunological consequence of CD39 has 
begun to be revealed.  Under a variety of disease models including inflammatory 
bowel disease, contact hypersensitivity and lung injury CD39-defecient mice 
developed exacerbated inflammation compared to their wild-type counterparts 47. 
Additionally, cells may express other ecto-enzymes capable of hydrolyzing 
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extracellular ATP including ectonucleotide pyrophosphatases (ENPPs), which 
hydrolyze ATP directly to AMP and pyrophosphate.    
The final adenine metabolite generated from ATP hydrolysis is adenosine, 
in which the single phosphate group of AMP is removed. This is achieved by 
either the sole ecto-5’-nucleotidase, CD73, or by non-specific alkaline 
phosphatases. Mice lacking CD73 exhibit augmented inflammatory responses 
similar to CD39-deficient mice suggesting that the concerted effort of these ecto-
enzymes to completely hydrolyze extracellular ATP into adenosine is a vital 
immunoregulatory mechanism for the ultimate protection of the host.  It is 
important to note that although these mouse models have established a role for 
CD39 and CD73 in the control of inflammation, it remains elusive which cell types 
are responsible for mediating these observations as these mice were not 
engineered as cell or tissue-specific conditional knockouts. 
Adenosine receptor signaling 
 
Extracellular adenosine levels are less than 1µM during normal physiological 
states; however it has been shown in various models that adenosine levels 
increase 10-100 fold during inflammatory pathological conditions.  In patients 
with sepsis, systemic adenosine concentrations were determined to be 4-10µM 48 
and in the synovial fluid of rheumatoid arthritis patients, adenosine is in the 10-
100µM range 49.  Therefore, elevated extracellular adenosine may arise in 
response to immunological threats.  Interestingly, is believed that the rise of 
extracellular adenosine levels is largely due to the extracellular metabolism of 
adenine nucleotides into adenosine. In contrast to excessive levels of 
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extracellular ATP, uncontrollable levels of extracellular adenosine can be 
detrimental to the host.  Adenosine deaminase (ADA) irreversibly deaminates 
adenosine into inosine, thereby modulating adenosine levels.  Individuals who are 
genetically deficient for ADA develop severe combined immunodeficiency (SCID) 
and exhibit significantly higher levels of adenosine in tissue and sera 50.  Although 
ADA was originally described as a strictly cytosolic enzyme, it has recently been 
shown that cells can release ADA into the extracellular milieu, thereby altering 
extracellular adenosine levels as well 47.  The notion that consistently high 
extracellular adenosine levels are associated with SCID underscores the concept 
of adenosine as an important modulator of the immune response.  Furthermore, 
it has been observed that human newborn serum exhibits significantly more 
adenosine compared to adults.  In the same study, the authors suggest that 
adenosine may act to dampen neonatal Th1 responses to protect the developing 
fetus as evidenced by the lower TNFα present in newborn serum compared to 
the adult counterparts 51.  However, the investigators did not evaluate the 
mechanism by which adenosine modulates TNFα production, thus it is believed 
that ATP and adenosine play essential, yet opposing roles in determining the 
outcome of disease. 
Adenosine receptors are guanine nucleotide-binding protein (G-protein) 
coupled receptors (GPCRs).  GPCRs consist of seven transmembrane domains 
with an extracellular amino terminus and a cytosolic carboxy-terminus that is 
coupled to a heterotrimeric G-protein signaling complex to induce intracellular 
signaling. The four adenosine receptors are expressed across species in human 
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and mice and exhibit differences with regard to G-alpha protein association and 
affinity to their ligand, adenosine. Both A1 and A3 receptors are coupled to Gαi 
proteins, which inhibit adenylyl cyclase activation and intracellular cAMP 
formation.  In contrast, both A2 receptors couple to the stimulatory G protein, 
Gαs, which stimulate adenylyl cyclase activity and enhances intracellular cAMP 
levels 52.  In addition, the A1R and A2aR demonstrate greater affinity for 
adenosine than the A2bR and A3R receptors; however it is important to highlight 
that these demonstrations were established under conditions in which each 
receptor was separately, ectopically expressed in a cell-line culture system.  
Thus, the relative activation threshold for these receptors under physiological 
conditions remains elusive. Moreover, there remains a lack of understanding 
regarding how each of these receptors is regulated with regard to macrophage 
biology.  
Through the generation of genetic knockout mice, a greater understanding of 
the role of adenosine receptors in immunological responses has been 
established.  Interestingly, however, the A2b receptor appears to be upregulated 
during pathological conditions, consistent with the notion that as extracellular 
adenosine levels increase in response to perilous conditions, the A2bR may be 
required to mediate appropriate adenosine-dependent responses.  
 




 The purinergic signaling system represents a highly regulated mechanism 
capable of dictating the course of action in response to not only homeostatic 
conditions such as muscle contraction and nerve function, but also in response to 
pathological settings such as infection and inflammatory disease. For these 
reasons, a variety of purinergic signaling-specific drugs are currently in clinical 
trials for the treatment of diabetic ulcers, chronic pulmonary obstruction disease 
(COPD) and aspirin-induced gastric injury 53. However, it is imperative that we 
understand the consequence of purinergic signaling on specific cell types and 
under various homeostatic and pathological conditions in order to design 
effective treatment strategies without compromising the patient’s overall health 
and ability to fight infections. Although, a greater understanding of the role each 
member of this purinergic system has been achieved through the development of 
genetic knockout mice, the bulk of these studies obscure the specific contribution 
of individual cell types in the development of the pathology observed, since the 
use of whole body knockout mice were used in which the gene has been deleted 
from all cells in the body. Importantly, however, there remains a significant under-
appreciation and demonstration for the specific contribution these molecules 
have in regulating macrophage physiology.  Because macrophages represent an 
integral part of both the progression and attenuation of inflammation, improving 
our understanding of how macrophage activation is regulated is important in the 
development of novel treatments for pathologies in which macrophages play an 
essential role.  
 




Chapter 2:  TLR stimulation initiates a CD39 based 
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Failure to control inflammatory macrophage activation responses can lead 
to pathological diseases, best exemplified by sepsis.  Despite our growing 
understanding of its pathogenesis, sepsis continues to affect more than 200,000 
people annually in the US with a mortality rate as high as 50% 12, 55.  The severe 
pathology associated with sepsis occurs in response to the hyper-production of 
macrophage-derived inflammatory cytokines, which can lead to vascular and 
tissue destruction, multiple organ failure, shock, and death 13.  Intriguingly 
though, macrophages isolated from late-stage septic individuals exhibit the 
phenotype of immunosuppressive, regulatory macrophages, expressing high 
levels of the anti-inflammatory cytokine IL-10, and low levels of TNFα and IL-12 
14, 15, 56.  These observations suggest the transition from inflammatory to 
immunosuppressive macrophages may be critical to control initial inflammatory 
responses and prevent lethal septic shock 14, 57, 58.  However, the molecular 
mechanism by which this transition is achieved remains poorly understood.  
In the present work, we examine the role that endogenous CD39 and ATP 
play in regulating the macrophage inflammatory response.  Recently, 
extracellular ATP (eATP) has been characterized as a ‘danger signal’ that can 
promote inflammation through P2X7-dependent activation of the NLRP3 
inflammasome leading to IL-1β production 19, 59-61.  Importantly, however, such 
results were shown to be dependent on the addition of millimolar levels of 
exogenous ATP in vitro.  These high levels of eATP have yet to be discovered in 
vivo, and the concentration of eATP is carefully controlled by the ecto-nucleoside 
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triphosphate diphosphohydralse (ENTPDase1/CD39) 62, 63.  It was recently 
shown macrophages express CD39, and that it played a role in modulating the 
P2X7-dependent production of IL-1β 64 in the presence of exogenously added 
ATP.  Several issues remain incompletely understood regarding how ATP and 
CD39 contribute to the regulation of macrophage activation.  First, the potential 
for macrophages to be an endogenous source of ATP has not been fully 
addressed. Unlike most cells, macrophages primarily generate ATP through 
glycolysis 65, 66. Moreover, macrophages increase the rate of glycolysis in 
response to TLR stimulation 67.  Previous attempts to measure ATP release from 
macrophages have yielded inconsistent results 68-70 that were likely complicated 
by endogenous CD39 activity.  Second, if macrophages are indeed a source of 
ATP, the mechanism by which they release ATP into the extracellular milieu has 
not been previously defined. Third, there is currently a paucity of studies 
investigating how ATP and CD39 influence inflammasome-independent 
responses, such as TNFα production 14, 58, 71.  Finally, the specific contribution of 
CD39 on macrophages in directing the course of inflammatory disease remains 
unknown. 
In the present study, we demonstrate that in response to a variety of TLR 
ligands, macrophages synthesize, secrete, and hydrolyze ATP to control their 
own activation status.  Surprisingly, the ATP that is generated does not stimulate 
IL-1β release but rather suppresses the production of pro-inflammatory cytokines 
like TNFα and IL-12.  Mechanistically, we show that macrophages hydrolyze self-
released ATP via CD39, to generate immunosuppressive adenosine.  CD39-
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mediated adenosine generation results in a dramatic reprogramming of the 
macrophage activation response, to enhance not only IL-10 production, but also 
many newly identified regulatory macrophage-specific transcripts 1, 6, 7, 72.  Finally, 
we demonstrate that macrophage-specific expression of CD39 is critical in 
preventing lethal hyper-inflammatory responses to LPS in vivo.  Taken together, 
our data indicate that CD39 acts as a “molecular switch” that controls the balance 
between inflammatory and regulatory macrophage differentiation.  
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Materials and Methods 
 
Mice and macrophage isolation. BALB/c and C57BL/6 mice were purchased 
from the Charles River Laboratories. These studies were reviewed and approved 
by the University of Maryland Institutional Animal Care and Use Committee. Bone 
marrow-derived macrophages were prepared from 6-8 week old female Balb/c, 
C57BL/6, Cd39-/-  73; and A2br-/-  74 mice, as previously described 75 and 
differentiated in 20% L929 (LC14) conditioned media unless otherwise noted.  
Human monocytes were obtained from healthy volunteers with their informed 
consent and IRB approval.  Monocytes were purified for immediate use or 
differentiated in the presence of 50ng/mL M-CSF (CSF-1) for 7 days as previously 
described 76.   Murine peritoneal macrophages were isolated as previously 
described 77. RAW264.7 cells (TIB-71TM) were obtained from ATCC (Manassas, 
VA).  
 
Reagents. ATP, ADP, AMP, adenosine, clodronate, pyrophosphate, phosphate, 
ATPγs, apyrase, adenosine deaminase, 2-deoxy-glucose, CBX, FFA and LPS E. 
coli K-235 were purchased from Sigma-Aldrich (St. Louis, MO). Pam3CSK4, Heat-
killed L. monocytogenes (HKLM), Poly(I:C) LMW, and Ultra Pure LPS E. coli K12 
were purchased from InvivoGen (San Diego, CA). POM-1 and 10Panx were 
purchased from Tocris Bioscience (R&D Systems; Minneapolis, MN).  
 
Stimulation conditions. All in vitro experiments were performed at 1-2x106c/mL in 
tissue culture treated plates. Mouse macrophages studies were performed in 
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DMEM/F12+GlutaMax (Gibco, Life Technologies;, Grand Island, NY) 
supplemented with 10% FBS, 1% pen/strep, and 1% glutamine (Gibco, Life 
Technologies;, Grand Island, NY) unless otherwise indicated.  Human 
monocyte/macrophage studies were performed in RPMI1640 (Gibco, Life 
Technologies; Grand Island, NY) supplemented with 10% FBS, 1% pen/strep, and 
1% glutamine (Gibco, Life Technologies;, Grand Island, NY).  For all experiments, 
monocytes/macrophages were co-stimulated in the presence of 100mM ATP and 
108cells/mL heat-killed L. monocytogenes, 1µg/mL Pam3CSK4, 10µg/mL Poly(I:C), 
or 10ng/mL Ultra Pure LPS unless indicated otherwise.  
 
Adoptive Transfer and in vivo LPS challenge. 1x106 BMDMs from Cd39-/- or 
wild-type littermate controls were injected i.p. into 6-8 week old female C57BL/6 
mice and challenged with 300µg LPS E. coli K-235 i.p. For survival experiments, 
mice were monitored twice daily for survival for 5 days.  
 
Gene Expression Analysis. Total RNA was isolated by using TriZol (Invitrogen, 
Life Technologies;, Grand Island, NY) and converted to cDNA using the 
ThermoScript Kit (Invitrogen, , Life Technologies) according to the manufacture’s 
protocol. qPCR analysis was performed using a LightCycler 480 Real-Time PCR 
System (Roche Diagnostics Corporation-Roche Applied Science;, Indianapolis, IN) 
and GoTaq qPCR Master Mix (Promega;, Madison, WI). Primer pairs used to 
amplify specific gene products are listed in Table 1. Relative expression levels 
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were calculated using the ΔΔCt method 6.  Gapdh was used as the housekeeping 
gene for normalization. 
 
Flow Cytometry Antibodies and Analysis. CD39 expression on peritoneal 
macrophages was determined after gating on F4/80+CD11b+ cells. CD39 
expression on human monocytes/macrophages was determined after gating on 
CD14+ cells. Anti-mouse CD16/32 was purchased from AnaSpec (Freemont, CA). 
Human Fc blocking reagent was purchased from Miltenyi Biotech Inc. (Auburn, 
CA). Anti-mouse CD39-AF647 (24DMS1) was purchased from eBioscience (San 
Diego, CA). Anti-mouse F4/80-pacific blue (BM8) and anti-human CD39-PE (A1) 
were purchased from BioLegend (San Diego, CA). Anti-mouse CD11b-FITC 
(M1/70) and anti-human CD14-PerCP (MφP9) were purchased from BD 
Biosciences (San Jose, CA). Samples were analyzed on a BD FACSCanto (BD 
Biosciences). Data were analyzed using FlowJo software (Tree Star, Inc., Ashland, 
OR). 
 
Secreted Cytokine Detection. Cytokine production was determined by a 
sandwich ELISA using specific capture and biotinylated detection antibody pairs: 
anti-mouse TNF-purified (G281-2626), TNF-biotin (MP6-XT3), IL-12/23p40-purified 
(C15.6), IL-12/23p40-biotin (C17.8), IL-10-purified (JES5-2A5), IL-10-biotin (JES5-
16E3), and anti-human TNF OptEIA kit were purchased from BD Biosciences (San 
Diego, CA) 6, anti-human IL-12/23p40 module set and anti-human IL-10 Ready-
Set-Go! Kit were purchased from eBioscience (San Diego, CA) 
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ATP Release Assay.  eATP release was performed in performed in 200µL serum-
free media.  Luminescence was detected using a Centro XS3 LB 960 Microplate 
Luminometer (Berthold technologies; Bad Wildbad, Germany). 
 
Inorganic Phosphate Release Assay. Phosphate release was performed in 
500µL nucleotidase buffer (154mM NaCl, 2mM KCl, 4mM MgCl2, 18mM NaHCO3, 
25mM HEPES pH7.4 and 10mM D-glucose). 
 
Thin Layer Chromatography (TLC). Experiments were performed in 200µL 
nucleotidase buffer containing 0.02mCi 14C-ADP (PerkinElmer; Waltham, MA). 
Supernatants were spotted onto polyethylenimine cellulose TLC plates (Sigma-
Aldrich;St. Louis, MO) and placed in a humidifying chamber containing filter paper 
and solvent containing 4M ammonium sulfate and 1.5M KH2PO4 in water at 1:1.5. 
Luminescence was detected using a FLA7100 Fugifilm Life Science 
Phoshorimager following a 24 hr exposure to phosphorimager film (GE Healthcare 
Biosciences; Pittsburg, PA).  
 
Nuclear Magnetic Resonance (NMR) spectroscopy. Samples were prepared in 
500µL nucleotidase buffer and supernatants were stored at -80ºC until NMR 
analysis. Immediately prior to NMR, samples were further supplemented with 10% 
Deuterium Oxide (D2O) (Cambridge Isotope Laboratories, Inc.; Andover, MA) to 
serve as the lock signal. The 31P spectra were collected at 37ºC using a Bruker 
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Avance-600MHz spectrometer, with a Bruker broadband SMART probe (Bruker 
BioSpin Corporation; Billerica, MA).  NMR data were collected using Topspin 
Version 2.1 and Icon Automation NMR software and NMR CaseTM multi-sample 
carousel.  31P spectra were acquired with an offset of -20 ppm, sweep width of 
24.271 Hz (~100 ppm), 65536 complex points and 1024 scans.  All spectra were 
processed using Topspin Version 1.3. 
 
Statistical Analysis. Data analysis was performed using GraphPad Prism 
software (GraphPad Software Inc.; La Jolla, CA) and analyzed using the 
Student’s t test. Kaplan-Meier survival curves were determined using the log-rank 
test. The statistical differences between groups, with the p-values are indicated in 
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Results 
TLR stimulation results in ATP release from macrophages 
 
The potential for macrophages to be a source of eATP remains 
controversial.  To address this, macrophages were stimulated with TLR agonists 
and the release of ATP was measured.  All TLR agonists tested were capable of 
inducing significant ATP release from the macrophage-like cell line RAW264.7 
(Figure 1A).  TLR-induced ATP release was glycolysis-dependent as treatment 
with 2-deoxyglucose, a competitive inhibitor of glycolysis 78, inhibited ATP 
release (Figure 1B).   Pannexin-1 is a plasma membrane channel that was 
recently shown to be the major mediator of ATP release from red blood cells 79 
and activated T cells 80.  To investigate whether pannexin-1 channels were 
important for ATP release from macrophages, RAW264.7 cells were stimulated 
with LPS in the presence of 10Panx, a pannexin-1 specific inhibitor 60, and the 
release of ATP was measured. The results revealed that ATP secreted by 
macrophages was strongly dependent on pannexin-1 (Figure 1C). The blockade 
of pannexin-1-mediated ATP release was also recapitulated when macrophages 
were stimulated with LPS in the presence of carbenoxolone (CBX), but not in the 
presence of flufenamic acid (FFA), which preferentially inhibits pannexin and 
related connexin channels, respectively 81 (Figure 1C).  Thus, these results 
suggest that pannexin-1 channels are indeed the major conduits from which ATP 
is released from TLR-stimulated macrophages.  
  
 




Figure 1. TLR stimulation results in ATP release from macrophages.  (A) RAW264.7 cells 
were stimulated with the indicated TLR stimuli or left untreated. After 3 hrs, ATP released was 
measured. The means +/- SEM of 3 independent experiments are shown and statistical analysis 
is relative to naïve samples.  (B) RAW264.7 cells were stimulated with LPS in absence or 
presence of 200µg/mL 2-DG and levels of ATP released was measured 3 hrs later. The means 
+/-SD of triplicate determinations are shown and are representative of 2 independent 
experiments. (C) RAW264.7 cells left untreated or stimulated with LPS alone or in the presence 
of 50µM 10Panx, 10µM CBX, or 10µM FFA.  After 3 hrs ATP released was measured. The means 
of 3 independent experiments +/- SEM are shown.  
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Differential CD39 expression on macrophage cell types 
 
Surprisingly, very little eATP was detected from LPS-stimulated bone 
marrow-derived murine macrophages (BMDMs) relative to LPS-stimulated 
RAW264.7 cells (Figure 2A), despite similar expression levels of pannexin-1 both 
at the mRNA and the protein level (Figure 2B,C).  We hypothesized that BMDMs 
may control the bioavailability of self-released eATP and express higher levels of 
CD39, thereby decreasing eATP detection.  Indeed, Cd39 transcript levels were 
below detection in RAW264.7 cells, but present in BMDMs (Figure 2B).   CD39 
expression on the surface of RAW264.7 cells was 10-fold less than on BMDMs 
(Figure 2D).  We further evaluated whether culture conditions used to develop 
BMDMs influenced CD39 expression and observed that CD39 levels were 
significantly higher on L929 and M-CSF differentiated BMDMs compared to GM-
CSF-induced BMDMs (Figure 2E. Furthermore, L929/M-CSF differentiated 
BMDMs most closely resembled peritoneal-resident macrophages with regard to 
CD39 expression.  These observations are consistent with previous work 
showing that in vitro cultivation of BMDMs in the presence of M-CSF is a more 
representative model of tissue resident macrophages than GM-CSF derived 
BMDMs 82.  Human monocytes and macrophages also expressed high levels of 
CD39 (Figure 2F).  
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Figure 2. CD39 is differentially expressed on macrophage cell types. (A) Levels of ATP 
released from LPS-stimulated RAW264.7 cells (open squares; dashed line) or BMDMs (closed 
squares; solid line) was measured over time. The means +/- SEM of 3 independent experiments 
are shown. (B) The mRNA expression of Panx1 and Cd39 in RAW264.7 cells and BMDMs. Data 
are representative of 3 independent experiments. (C) The PANX1 expression was detected by 
Western Blot in RAW264.7 cells and BMDMs.  GAPDH was probed for loading control, Data are 
representative of 2 independent experiments. (D) The surface expression of CD39 on RAW264.7 
cells and BMDMs was determined by FACS and expressed as ΔMFI, compared to the isotype 
control for each group. The means +/- SD of triplicate determinations are shown and are 
representative of 3 independent experiments. (E) CD39 expressed on peritoneal macrophages 
and BMDMs differentiated in the presence of L929 conditioned media, M-CSF or GM-CSF for 7 
days was determined by flow cytometry and expressed as  ΔMFI, compared to isotype control for 
each group. The mean +/- SD of triplicate determinations is shown and is representative of 2 
independent experiments. (F) Analysis of CD39 surface expression (black histograms) on human 
monocytes (left) and macrophages (right) compared to isotype controls (gray histograms). Data 
are representative of 3 independent experiments.  
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CD39 controls eATP levels released by macrophages 
 
To address whether CD39 was directly responsible for regulating levels of 
macrophage-derived eATP, we examined the levels of ATP released from LPS-
stimulated Cd39-/- macrophages.  In contrast to wild-type macrophages, eATP 
was detectable following LPS stimulation, and sustained for up to 24 hours post 
activation in Cd39-/- macrophages (Figure 3A). These data suggest that TLR-
stimulated wild-type macrophages, secrete ATP but rapidly hydrolyze it, therefore 
preventing eATP detection. Furthermore, similar to CD39lo RAW264.7 cells, ATP 
secretion by Cd39-/- macrophages was critically dependent on pannexin-1 (Figure 
3B). Taken together, these data demonstrate that TLR stimulation induces 
intrinsic ATP release from macrophages via pannexin-1 channels, and under 
normal conditions macrophages utilize CD39 to control eATP bioavailability.  
 
      
      
Figure 3. CD39 controls eATP levels released by macrophages. (A) Levels of ATP released 
from LPS-stimulated Cd39-/- (open squares; dashed line) and wild-type (closed squares; solid 
line) BMDMs were measured over time. The means +/- SEM of 3 independent experiments are 
shown. (B) The levels of ATP produced by Cd39-/- BMDMs stimulated with LPS in the absence 
(open squares; dashed line) or presence (closed circles; solid line) of 50µM 10Panx was 
measured over time.  The means of 3 independent experiments +/- SEM are shown.  
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Extracellular ATP is rapidly hydrolyzed by macrophage ecto-enzymes 
 
Having demonstrated that CD39 is important for regulating the levels of 
macrophage-derived eATP, we next characterized the CD39-specific e-NTPDase 
activity in macrophages.  ATP hydrolysis yields the production of adenine 
metabolites and inorganic phosphates (Pi), therefore we first examined levels of 
Pi released over time by RAW264.7 cells and BMDMs in the presence of eATP.  
Consistent with the CD39 expression data, CD39lo RAW264.7 cells exhibited 
substantially impaired eATP hydrolysis compared to CD39+/+ BMDMs (Figure 
4A).  eATP hydrolysis by macrophages was also dependent on CD39, as 
treatment with the CD39 inhibitor POM-1 83 as well as CD39-deficient 
macrophages exhibited, substantially impaired ATP hydrolysis (Figures 4B and 
4C).  The defects in purine nucleotide hydrolysis were specific to ATP and ADP, 
but not AMP (Figure 4D)62. We next investigated whether genetic ablation of 
Cd39 could be rescued by the presence of apyrase, a soluble e-NTPDase 84.  
Indeed, apyrase fully complemented the loss of endogenous CD39, achieving 
hydrolysis rates similar to Cd39+/+ macrophages (Figure 4D).  The low level of 
ATP hydrolysis by CD39-deficient macrophages may be due to the presence of 
low affinity non-specific phosphatases.  To address this, we compared hydrolysis 
over time from macrophages exposed to lower levels of ATP and demonstrate 
that wild-type macrophages completely hydrolyze 5µM ATP within 15 minutes, 
compared to 30% of 500µM ATP hydrolyzed within the same time (Figure 4E).  
Importantly, macrophages lacking CD39 exhibited substantially reduced 
hydrolysis rates regardless of the amount of eATP present.  
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Figure 4. Kinetics and substrate specificity macrophage-CD39. (A-C) The hydrolysis of 
500µM ATP by wild-type BMDMs (closed squares; solid black line) over time compared to 
RAW264.7 cells (open squares; gray, dashed line) (A), in the presence of 10mM POM-1 (open 
squares; black, dashed line) (B), or Cd39-/- (open squares; black, dashed line) BMDMs (C) and 
was measured by the inorganic phosphate (Pi) release assay. (D) The percent of adenine 
nucleotides hydrolyzed within 30 min. as measured by inorganic phosphate (Pi) released by wild-
type BMDMs (solid bars) and Cd39-/- (striped bars) BMDMs in the absence (left) or presence of 
apyrase (right). (A-D) The means +/- SD of triplicate determinations are shown and are 
representative of 3 independent experiments. (E) The percent of 5µM (open squares) or 500µM 
(closed squares) ATP hydrolyzed over time by wild-type BMDMs (solid lines) and Cd39-/- (dashed 
lines) BMDMs.  Percent of hydrolysis was compared to levels of ATP detected in the absence of 
cells and determined by the ATPlite assay. The data are representative of 3 independent 
experiments.  
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  To further elucidate the CD39-specific e-NTPDase activity in 
macrophages, we utilized 31P NMR spectroscopy, which enables the 
identification of each phosphorus-containing intermediate metabolite generated 
via eATP hydrolysis.  NMR revealed that ATP remained intact and stable in 
macrophage-free culture medium for several hours (Figure 5A); however, eATP 
stability was drastically reduced in the presence of CD39+/+ macrophages as 
evidenced by the generation of ADP and AMP from ATP.  By 4 hours, ATP was 
completely hydrolyzed (Figure 5B). In contrast, a substantial fraction of ATP 
remained intact, even after 8 hours of exposure to Cd39-/- macrophages (Figure 
5C).  While some ATP/ADP was hydrolyzed by CD39-deficient macrophages, 
which is likely due to the compensatory non-specific phosphatases, the rate of 
conversion of eATP to ADP and then AMP was dramatically reduced. 
Collectively, these data suggest that CD39 is the major, high-affinity ecto-
ATPase utilized by macrophages to hydrolyze eATP.  
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Figure 5. 31P NMR analysis of eATP hydrolysis kinetics by macrophages. (A-C) The 31P 
NMR spectra of 500µM ATP alone (A) or in the presence of by wild-type (B) or Cd39-/- BMDMs 
(C) are shown over time. The location of the α,β,γ phosphorous peaks of ATP (black circles), α,β 
phosphorous peaks of ADP (gray circles), phosphorous peaks of AMP (white circles), inorganic 
phosphate (black diamonds) was based on reference 31P NMR spectra. NMR spectra are 
representative of at least 3 independent experiments.  
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eATP promotes regulatory macrophage development following TLR 
stimulation 
 
Although the inflammatory effect of millimolar levels of eATP is well 
documented 19, 59, 60, 85, the role of sub-millimolar levels of eATP in influencing 
macrophage physiology remains unresolved.  To address this, macrophages 
were stimulated with LPS in the presence or absence of 100 µM ATP, and 
genetic biomarkers associated with inflammatory and regulatory macrophage 
activation states were assessed.  Macrophages stimulated with LPS alone 
upregulated the expression of mRNA encoding the inflammatory cytokines TNFα 
(Figure 6A) and IL-12/23p40 (Figure 6B), as expected.  Macrophages stimulated 
in the presence of low levels of ATP, suppressed Tnfα and Il-12/23p40 
transcripts by ~80% and 60%, respectively (Figure 6A,B).  Additionally, a 
significant upregulation of many transcripts expressed by regulatory 
macrophages was observed including Il-10, Il-33, Hb-egf, and Sphk1 1, 6, 7, 72.  
Although eATP enhanced LPS-induced Arg1 levels, it did not induce expression 
of Fizz1, Ym1, Mrc1, Msr1, or Fabp4, which are biomarkers of alternatively 
activated (IL-4/IL-13 treated) macrophages (AAMs) 86-88 (Figure 6C).  Thus, eATP 
did not merely inhibit inflammatory macrophage activation, but rather actively 
promoted the development of a regulatory macrophage phenotype. 
 The addition of ATP to macrophages also attenuated TNFα (Figure 6D) 
and IL-12/23p40 (Figure 6E) protein secretion and increased IL-10 production 
(Figure 6F).  These cytokine modulations were dose dependent and were 
achievable within the range of ATP released intrinsically from TLR-activated 
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macrophages (Figures 6G).  Furthermore, the decrease of inflammatory cytokine 
production and the induction of IL-10 release were not specific to LPS 
stimulation, since eATP also promoted regulatory macrophage differentiation in 
response to a variety of other TLR agonists (Figure 6H).  We further tested 
whether CD39 contributed to the development of ATP-induced regulatory 
macrophages by activating macrophages in the presence of POM-1, which 
resulted in complete reversal of ATP-mediated immunosuppression and blocked 
the induction of a regulatory activation state in mouse (data not shown) and 
human macrophages (Figure 6I).  Together, these results demonstrate that 
macrophages utilize CD39 and eATP to regulate their activation status towards a 
regulatory phenotype.   
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Figure 6. eATP promotes regulatory macrophage development. (A-B) Tnfα (A) and Il-
12/23p40 (B) mRNA expression in naïve wild-type BMDMs or BMDMs stimulated with LPS in the 
absence or presence of 100µM ATP was determined after 4 hrs of stimulation. The means of 3 
independent experiments +/- SEM are shown. (C) The percent increase of regulatory 
macrophage-associated transcripts in wild-type BMDMs in the presence of LPS and 100mM ATP 
are shown at 4 hrs post-stimulation by qRT-PCR. The dashed line represents the expression of 
regulatory transcripts induced by LPS alone. The means of at least 3 independent experiments 
+/- SEM are shown. (D-F) Secreted levels of TNFα   (D), IL-12/23p40 (E) and IL-10 (F) by wild-
type BMDMs stimulated with LPS in the absence or presence of 100µM ATP at 8 hrs post-
stimulation. The means of 5 independent experiments +/- SEM are shown. (G) TNFα   (closed 
squares; black line), IL-12/23p40 (open squares; black line) and IL-10 (closed squares; gray line) 
secreted by wild-type BMDMs stimulated with LPS in the presence of increasing concentrations 
of ATP.  Cytokine levels were determined after 8 hrs by ELISA. The means +/- SD of triplicate 
determinations are shown and are representative of 3 independent experiments. (H) The percent 
of TLR-induced cytokines produced in the presence of 100 µM ATP. Cytokine levels were 
determined after 8 hrs by ELISA and are relative to TLR stimulation alone (dashed line). The 
means of TNFα   (black bars), IL-12/23p40 (striped bars) and IL-10 (gray bars) production +/- SD 
of triplicate determinations are shown and are representative of 3 independent experiments. 
Statistical analysis is relative to samples stimulated with TLR stimuli alone. (I) LPS-induced TNFα 
(black bars), IL-12/23p40 (striped bars) and IL-10 (gray bars) production by human macrophages 
exposed to 100µM ATP alone or in the presence of 10µM POM-1 was determined by ELISA at 8 
hrs post-stimulation. The means +/- SD of triplicate determinations are shown and are 
representative of 2 independent experiments. 
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ATP-derived adenosine modulates inflammatory macrophage activation 
 
Having demonstrated that low levels of eATP have a previously 
unrecognized influence in directing regulatory macrophage development, we next 
sought to determine the molecular mechanism underlying this phenomenon.  To 
address whether eATP hydrolysis contributed to regulatory macrophage 
induction by eATP, TNFα, IL-12/23p40 and IL-10 production by macrophages 
stimulated in the presence of the non-hydrolyzable ATP analog, ATPγs were 
measured.  In contrast to ATP, ATPγs did not inhibit LPS-induced TNFα or IL-
12/23p40 production, nor did it enhance IL-10 secretion (Figure 7A).  These data 
therefore suggest that hydrolysis of eATP was required for the modulation of 
TNFα and IL-12 production.  To investigate which ATP metabolite(s) was 
responsible for attenuating TLR-induced inflammatory macrophage responses, 
we exposed macrophages to LPS in the presence of ADP, AMP, and adenosine 
and observed that each adenine metabolite suppressed TLR-induced TNFα and 
IL-12/23p40 production, while enhancing IL-10 production (Figure 7B).  Although 
pyrophosphate has been shown to influence IL-1β production from macrophages 
89, phosphate, pyrophosphate nor its non-hydrolyzable analog clodronate altered 
TNFα, IL-12/23p40, or induce IL-10 production from macrophages (Figure 7B).  
Because adenosine has been associated with immunosuppression 90, 91, we 
examined whether macrophages were capable of generating adenosine from 
adenine nucleotides by TLC.   Macrophages produced AMP within 15 minutes of 
exposure to ADP, and by one hour, substantial adenosine generation was 
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evident by TLC (Figure 7C).  Within 2 hours, virtually all the ADP provided to the 
cells was converted to AMP and adenosine. Thus, the TLC data are consistent 
with the NMR results (above) and indicate that macrophages convert 
extracellular adenine nucleotides to adenosine. 
To further implicate macrophage-generated adenosine as a key 
immunomodulatory mediator, we assessed cytokine production by macrophages 
stimulated in the presence of adenosine deaminase (ADA), which rapidly 
converts adenosine into inosine thereby effectively removing adenosine from the 
culture.  The addition of ADA to macrophages prevented the ability of adenosine 
or ATP to inhibit LPS-induced TNFα (Figure 4D) and IL-12/23p40 production 
(Figure 7E).  ADA also blocked adenosine and ATP-enhancement of IL-10 
production (Figure 7F).  Thus, induction of the regulatory macrophage phenotype 
by eATP requires macrophage hydrolysis of ATP to adenosine. 
  
 





Figure 7. ATP-derived adenosine modulates inflammatory macrophage activation.  (A) 
Wild-type BMDMs were stimulated with LPS in the absence or presence of 100 µM ATP or non-
hydrolyzable ATPγs and TNFα (black bars), IL-12/23p40 (striped bars), and IL-10 (gray bars) 
production was measured by ELISA 8 hrs later. The means of 3 independent experiments +/- 
SEM are shown. (B) Levels of TNFα (black bars), IL-12/23p40 (striped bars), and IL-10 (gray 
bars) produced by wild-type BMDMs stimulated with LPS in the absence or presence of 100µM 
ATP, ADP, AMP, adenosine, clodronate, pyrophosphate, or phosphate. Cytokine levels were 
measured by ELISA after 8 hrs. The means +/- SD of triplicate determinations are shown and are 
representative of 3 independent experiments. Percent of cytokine produced is relative to samples 
stimulated with LPS alone.   (C) The kinetics of 14C-ADP hydrolysis by resting macrophages over 
time (left) was determined by TLC. Hydrolysis controls consist of apyrase alone for 5 min (Apy), 
or apyrase in the presence of alkaline phosphatase (Apy/AP) and 14C-ADP (right).  Data are 
representative of at least 3 independent experiments. (D-F) Levels of TNFα  (D), IL-12/23p40 (E), 
and IL-10 (F) produced by wild-type BMDMs stimulated with LPS in the absence or presence of 
100mM ATP or adenosine in the absence or presence of 1 U/ml adenosine deaminase  (ADA).  
Cytokines were measured 8 hrs after stimulation by ELISA. The means +/- SD of triplicate 
determinations are shown and are representative of 3 independent experiments. 
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ATP-derived adenosine attenuates inflammatory cytokine production via 
A2bR signaling  
 
There are four known receptors for adenosine: A1R, A2aR, A2bR, and 
A3R.  qRT-PCR indicated that macrophages express low levels of transcripts for 
all four adenosine receptors (Figure 8A), and analysis of their expression over 
time revealed that adenosine receptor expression was dynamically regulated 
during macrophage activation (Figure 8B).  Naïve macrophages express A2aR 
most highly (Figure 8A), whereas the A2bR increased in response to LPS.  
Transcript levels of the other adenosine receptors declined over time (Figures 8A 
and 8B).  These data suggest that TLR stimulation selectively upregulates A2bR 
expression to increase the sensitivity of the macrophage to available adenosine 
within the extracellular milieu.   
To further study the role of the A2bR in mediating regulatory macrophage 
development, we examined A2br-/- macrophages following stimulation with LPS 
and ATP.  A2br-/- macrophages expressed significantly more inflammatory 
transcripts compared to wild-type macrophages (Figure 8C), and LPS-stimulated 
A2br-/- macrophages were functionally more inflammatory than their wild-type 
counterparts, secreting higher amounts of TNFα and IL-12/23p40 (Figure 8D). 
These data indicate that the A2bR was involved in the modulation of 
inflammatory cytokines. The A2bR was not essential for the regulation of IL-10 as 
the expression of Il-10 transcripts was not significantly different between A2br-/- 
and wild-type macrophages (Figure 8C). Interestingly, we observed an increase 
in A2ar expression in A2br-/- macrophages upon activation (Figure 8E) 
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suggesting macrophages may compensate for the absence of A2bR signaling by 
preferentially upregulating the A2aR.  Together, these results demonstrate that in 
response to LPS, macrophages upregulate the A2bR to respond to (ATP-
derived) adenosine to limit inflammatory macrophage responses.   
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Figure 8. ATP-derived adenosine attenuates inflammatory cytokine production via A2bR 
signaling. (A) Adenosine receptor mRNA expression in naïve (gray bars) or LPS stimulated 
(black bars) BMDMs at 4 hrs post-stimulation.  The means +/- SD of duplicates are shown and 
are representative of 3 independent experiments. (B) mRNA expression of A1r (black, closed 
squares; black line), A2ar (black, closed circles; black line), A2br (gray closed squares; gray, 
dashed line), and A3r (black, closed diamonds; black line) in BMDMs stimulated with LPS over 
time.  The means +/- SD of duplicates are shown and are representative of 3 independent 
experiments. (C) The percent of LPS-induced cytokine transcript expression modulated by 
100µM ATP in wild-type (solid bars) or A2br-/- (striped bars) BMDMs 4 hrs post-stimulation. The 
dashed line represents mRNA expression in BMDMs stimulated with LPS alone. The means of 3 
independent experiments +/- SEM are shown. (D) The percent of LPS-induced cytokine produced 
in the presence of 100µM ATP in wild-type (solid bars) or A2br-/- (striped bars) BMDMs was 
determined by ELISA at 16 hrs post-stimulation. The dashed line represents cytokine production 
induced by LPS alone. The means +/- SD of triplicates are shown and are representative of 2 
independent experiments. (E) A2ar and A2br mRNA expression in wild-type (solid bars) and 
A2br-/- (striped bars) BMDMs unstimulated (gray bars) or stimulated with LPS (black bars) was 
determined by qRT-PCR at 4 hrs post stimulation. The means +/- SD of duplicates are shown 
and are representative of 3 independent experiments. 
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CD39 blockade renders macrophages hyper-inflammatory  
 
Because CD39 initiates the hydrolysis cascade necessary to generate 
adenosine, we hypothesized that CD39 may function as an intrinsic regulator of 
the macrophage inflammatory response.  To address the functional significance 
of ATP release by macrophages on their own activation state, we examined the 
expression of cytokine mRNA from TLR-activated macrophages in the presence 
of POM-1.  Blocking ATP hydrolysis with POM-1 augmented LPS-mediated 
inflammatory cytokine expression, while significantly decreasing the production of 
Il-10 (Figure 9A-C). We also evaluated the kinetics of cytokine production by 
macrophages stimulated with LPS in the presence of POM-1, and found they 
secreted significantly more TNFα and IL-12/23p40 and less IL-10 over time 
compared to macrophages activated in the absence of POM-1 (Figures 9D-F).  It 
is important to highlight that these data were observed in the absence of 
exogenous ATP, thus revealing that CD39 blockade results in the failure to 
convert macrophage-released ATP into adenosine, thereby enhancing 
macrophage inflammatory responses.  
We next examined whether CD39 activity could also influence the duration 
of inflammatory macrophage activation. To do this, macrophages were briefly 
stimulated with LPS in the presence or absence of POM-1.  The LPS was then 
removed and the macrophages were re-cultured in fresh LPS-free media and 
cytokine release was measured over time. In the absence of POM-1, LPS-
stimulated macrophages decreased TNFα and IL-12/23p40 production shortly 
after the removal of LPS (Figures 9G and 9H).  In contrast, POM-1 treatment 
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resulted in the continued production of TNFα and IL-12/23p40, despite the 
removal of LPS from macrophage cultures (Figures 9G and 9H).  IL-10 secretion 
was not similarly affected, suggesting that LPS-induced IL-10 transcripts are 
inherently unstable (Figure 6I). 
 
Figure 9. CD39 blockade renders macrophages hyper-inflammatory.  (A-C) Tnfα (A), Il-
12/23p40 (B) and Il-10 (C) mRNA expression at 4 hrs post- stimulation in wild-type BMDMs 
stimulated with LPS in the absence (solid bars) or presence of 10µM POM-1 (striped bars). The 
means +/- SD of triplicate determinations are shown and are representative of 3 independent 
experiments. (D-F) Cytokine production by BMDMs stimulated with LPS in the absence (closed 
squares; solid line) or presence (open squares; dashed line) of 10µM POM-1. TNFα (A), IL-
12/23p40 (B) and IL-10 (C) levels were detected by ELISA. The means of at least 3 independent 
experiments +/- SEM are shown.  (G-I)  BMDMs were stimulated with LPS in the absence (closed 
squares; solid line) or presence (open squares; dashed line) of 10µM POM-1 then washed with 
PBS (break in y-axis) and replaced with LPS-free media and monitored over the next 5 hours for 
TNFα (D), IL-12/23p40 (E), and IL-10 (F) production. Protein levels was measured by ELISA. The 
means +/- SD of triplicates are shown and are representative of 3 independent experiments. 
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CD39-deficient macrophages exhibit impaired regulatory macrophage 
induction  
 
The function of macrophage-CD39 during inflammatory diseases remains 
poorly understood.  Therefore, inflammatory responses by Cd39-/- macrophages 
were compared to wild-type macrophages.  Similar to POM-1-treated 
macrophages, CD39-deficient macrophages produced significantly more TNFα 
and IL-12/23p40 and less IL-10 than their wild-type counterparts when exposed 
to LPS in vitro (Figure 10A). To investigate the role of macrophage-specific 
expression of CD39 in orchestrating a pro-inflammatory response in vivo, we 
adoptively transferred naïve Cd39-/- macrophages into the peritoneum of wild-
type mice.  These mice were then challenged with low levels of LPS and their 
survival was monitored over the next 5 days.  75% of mice that received Cd39+/+ 
macrophages survived, whereas only 25% of the mice that received Cd39-/- 
macrophages survived the endotoxin challenge (Figure 10B). Regulatory 
macrophage-specific biomarkers were also assessed in peritoneal cells from 
wild-type mice following adoptive transfer of either wild-type or CD39-/- 
macrophages after endotoxin challenge.  Consistent with the results generated in 
vitro (Figure 10A-C), CD39-deficient macrophages promoted significant 
enhancement of Tnfα and Il-12/23p40 expression in vivo (Figure 10C), while the 
induction of genes associated with regulatory macrophages including Il-10, Il-33, 
and Arg1 was significantly impaired (Figure 1C).  These results therefore suggest 
that normal transition from an inflammatory to regulatory macrophage activation 
state is important in preventing lethal septic pathology.  Taken together, these 
data demonstrate that CD39 expressed on macrophages is necessary to limit 
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endotoxin-induced lethality in vivo, and that the presence of relatively few Cd39-/- 





Figure 10. CD39-deficient macrophages exhibit impaired regulatory macrophage induction 
and enhance LPS toxicity in vivo.  (A) Levels of TNFα (black bars), IL-12/23p40 (striped bars), 
and IL-10 (gray bars) produced by wild-type and Cd39-/- BMDMs stimulated with LPS for 8 hrs.  
Cytokine production was determined by ELISA. The means +/- SEM are shown. (B) Kaplan-Meier 
survival curves of wild-type mice challenged with 300µg LPS (i.p.) 3 hrs after adoptive transfer 
(i.p) of wild-type (closed squares; solid line) or Cd39-/- BMDMs (open squares; dashed line). Data 
represent the means of 10 mice per group. (C) The expression of cytokine transcripts from ex 
vivo peritoneal cells was determined 1 hr post LPS challenge from wild-type mice receiving 1 x 
106 naïve wild-type (solid bars) or Cd39-/- (striped bars) BMDMs. The means of samples from 4 
mice per group +/- SEM are shown.   
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Discussion  
In response to infection macrophages produce inflammatory mediators 
that, if not appropriately regulated, have the potential to harm the host.  This is 
often manifested during sepsis 13, 15, 92, where a switch from inflammatory to 
immunosuppressive macrophages has been suggested to play a critical role in 
protecting the host from lethal septic shock 14, 57, 58.  However, the molecular 
mechanisms governing this transition remain poorly understood. In this study, we 
investigated the potential for macrophages to self-regulate their activation state 
during inflammation.   We demonstrate that the induction of inflammatory 
macrophage responses is accompanied by intrinsic purinergic regulatory 
mechanisms to limit the development of a hyper-inflammatory activation state. 
First, TLR-induced glycolysis results in the generation of ATP, a fraction of which 
is released through pannexin-1 membrane channels.  Second, following its 
release into the extracellular milieu, eATP is rapidly hydrolyzed via CD39 on 
macrophages.  Third, over the next 4 hours, TLR-activated macrophages convert 
ATP to adenosine and selectively upregulate endogenous A2bR expression, thus 
enhancing their sensitivity to ATP-derived adenosine.  Thus, these results 
illustrate a new model of macrophage activation that is centered upon their ability 
to inherently transition from an inflammatory to a regulatory activation state 
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Figure 11. A model depicting macrophage-intrinsic regulation of the activation response.    
Upon stimulation with LPS or other TLR ligands, macrophages assume an inflammatory 
activation status. (1.) Initially, they produce inflammatory mediators including TNFα and IL-12 
while at the same time releasing ATP into their local extracellular environment through Panx1 
channels (green) (2.) In the presence of CD39 (red), macrophages hydrolyze self-produced 
extracellular ATP to AMP (3.) Within the next 4 hours, macrophages further dephosphorylate 
AMP to generate adenosine while at the same time upregulating A2bAR expression (blue) (4.)  
Adenosine signals through primarily the A2bAR receptor to inhibit the production of inflammatory 
cytokines, and together with A2aAR-mediated signaling enhances immunoregulatory mediators 
(including IL-10, IL-33, HB-EGF and SphK1). In the absence of CD39, activated macrophages 
are unable to convert self-produced ATP to immunosuppressive adenosine and as a 
consequence are pushed to a hyper-inflammatory state of activation. 
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Therefore, in contrast to IL-1β-dependent inflammation driven by high 
levels of exogenous ATP 19, 59, 60, 85, our data demonstrate that endogenous ATP 
can negatively regulate macrophage activation.  The novelty of this work is the 
demonstration that TLR-mediated macrophage activation is normally transient, 
and that blockade of any steps of this newly defined macrophage-intrinsic 
regulatory cascade results in hyper-inflammatory macrophage responses.  
This work reveals for the first time, an essential role of macrophage-
specific CD39 in directing the course of inflammatory disease progression in vivo.  
To date, there are no animal models in which macrophages are the only cell type 
deficient in CD39; therefore the specific contribution of macrophage-CD39 to 
disease pathology has been unclear.  As demonstrated here, the transfer of 
small numbers of Cd39-/- macrophages into wild-type mice resulted in increased 
lethality in a murine model of septic shock. Furthermore, CD39-deficient 
macrophages maintained a hyper-inflammatory state and failed to transition into 
regulatory macrophages in vitro or in vivo. These data support previous reports 
suggesting that the ability of inflammatory macrophages to transition to an anti-
inflammatory state is vital to the survival of septic individuals 14, 56, 57 and reveals 
a novel role for macrophage-CD39 in mediating this transition.  
Although it has been well documented that macrophages exposed to 
exogenous adenosine exhibit immunomodulatory responses 52, 91, the present 
work expands this idea and demonstrates: 1) that TLR-activated macrophages, 
themselves represent an important source of eATP, 2) that macrophages rapidly 
and efficiently convert eATP to adenosine, 3) that this conversion is dependent 
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on CD39, and 4) that macrophages respond to eATP-derived adenosine by 
assuming a transcriptional profile that is characteristic of regulatory 
macrophages. Our data are consistent with previous reports suggesting a role for 
A2bR-mediated immunosuppression 93-95 and implicating the A2aR as the major 
adenosine receptor involved in IL-10 induction in macrophages 96.  Interestingly, 
both the A2aR and A2bR are G-protein coupled receptors (GPCRs) associated 
with the Gαs subunit and are capable of activating adenylate cyclase and 
enhancing intracellular cAMP levels 90.  We previously demonstrated that 
stimulating macrophages in the presence of cAMP led to the development of the 
regulatory phenotype 7 and the activation of GPCRs resulted in ERK-dependent 
IL-10 hyper-induction 8, 97.  Indeed, LPS-stimulated macrophages exposed to low 
levels of ATP/adenosine resulted in ERK activation and ERK-dependent IL-10 
production (data not shown), thereby supporting a role for ERK in driving 
adenosine-induced regulatory macrophage development. 
Importantly, in addition to IL-10, macrophages exposed to ATP upregulate 
a number of transcripts that are preferentially upregulated in regulatory 
macrophages compared to classically (M1) including IL-33, Sphk, and HB-EGF 1, 
6, 7, 72.  Some of these regulatory macrophage-specific transcripts have been 
associated with lung inflammation, however their expression is likely to be tissue-
dependent.  Indeed, the negative correlation between LPS toxicity and 
expression of these regulatory macrophage biomarkers in mice strongly suggests 
that these molecules promote immunosuppression.  Although Arg1 was 
upregulated in response to ATP, Arg1 may not be a reliable AAM-specific 
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biomarker, because it can be induced through IL-4/IL-13-independent 
mechanisms. Arg1 expression via STAT3-dependent 98 and cAMP-mediated 
pathways 99, 100 have been previously reported. Furthermore, although it was 
recently reported that adenosine augments IL-4-induced alternative activation in 
macrophages 101, we did not observe enhanced expression of any AAM-specific 
biomarkers in TLR-activated macrophages exposed to ATP.  Together, these 
observations indicate that TLR-activated macrophages exposed to eATP 
represent a state of activation distinct from AAMs.  
Homeostatic concentrations of eATP within tissues have been estimated 
to be within the nM-µM range 46, 102; however these values likely underestimate 
the level of eATP within local, pericullular environment. Furthermore, eATP levels 
have been shown to increase 10-100-fold during pathophysiological states 102, 
103.  Therefore, it will be interesting to understand the molecular control of ATP 
release from macrophages.    We did not observe any change in pannexin-1 
expression over time in macrophages suggesting that the induction of pannexin-1 
expression is not a point of regulating ATP release from macrophages. Recently, 
caspases 3 and 7 have been implicated in controlling pannexin-1 function in 
apoptotic cells 81, however the macrophages used in this study were not 
apoptotic.  Thus, ATP release is likely not due to caspase activation in these 
cells.  Interestingly, however we observed Hif1α expression and intracellular ATP 
levels increased substantially over the first 1-2 hours post stimulation (data not 
shown). Therefore, we predict that the activation of glycolysis needed to 
 
 68   
 
synthesize intracellular stores of ATP prior to secretion may represent an 
important checkpoint governing the kinetics of ATP release from macrophages. 
There are currently a number of adenosine-directed therapeutics under 
development to treat various inflammatory diseases 53, however none that 
specifically target macrophages.  Our data reveal that the release and 
subsequent hydrolysis of ATP is a previously unrecognized mechanism 
controlling the magnitude and duration of macrophage activation.  The ability for 
CD39-mediated ATP hydrolysis to direct regulatory macrophage development 
was shown to also be applicable to human monocyte and macrophages, thus 
highlighting the translational potential of this work.  The results of this study 
therefore broaden the spectrum of therapeutics that could be designed to treat 
diseases in which macrophage activation plays a contributing role 14.  
In summary, we have identified a novel macrophage-intrinsic regulatory 
pathway that may provide a mechanism to explain how macrophages are 
capable of playing disparate roles in the progression and the resolution of 
inflammation. This work further demonstrates that TLR-induced macrophage 
activation is a transient state that can be efficiently reversed, and that CD39 
serves a central role in orchestrating the transition from a pro-inflammatory to an 
immunoregulatory state of activation in macrophages.  
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Chapter 3:  IFNγ-mediated inhibition of the adenosine 2b 
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Although inflammatory macrophage activation is necessary to combat 
invading microbes, as resident protectors of host tissue, macrophages are 
additionally challenged to regulate themselves in order to fight infections without 
destroying their residing tissue and compromising the overall health of the host. 
Tissue destruction is a consequence of the persistent release of many 
macrophage-derived noxious molecules including nitric oxide (NO) and tumor 
necrosis factor α (TNFα).   Moreover, severe tissue pathology and inflammatory 
macrophages are shared characteristics between myriad diseases including 
type-2 diabetes, obesity, Alzheimer’s and autoimmune disorders14, 23, 24, 104.  
However, the underlying mechanisms sustaining chronic inflammation remain 
elusive.  
Due to their natural plasticity, macrophages possess the unique ability to 
actively participate in both the maintenance of tissue integrity and protection from 
pathogens.  Thus, once infection is controlled, inflammation must be resolved in 
order to retain homeostatic tissue function.  The exposure of macrophages to 
microbial toll-like receptor (TLR) stimuli initiates the production of inflammatory 
molecules, however such stimuli may concomitantly activate negative feedback 
mechanisms to restrict macrophage activation leading to the development of 
acute, short-lived inflammation.  We recently demonstrated that upon TLR 
stimulation, macrophages are glycolytically activated and release low levels of 
endogenous adenosine triphosphate (ATP) into their local extracellular milieu.  
Over the next 2-4 hours, macrophages actively convert this ATP into 
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immunosuppressive adenosine via CD39-mediated hydrolysis and transition 
towards an anti-inflammatory activation state.  Moreover, deficiency of CD39 
specifically on macrophages resulted in severe immunopathology in a mouse 
model of septic shock due to the inability of these cells to develop into regulatory 
macrophages. Thus, inflammation is limited as a consequence of adenosine 
generation and its signaling to prevent overactive inflammatory macrophage 
responses.  
The presence of high levels of interferon γ (IFNγ) represents an important 
differing quality between acute and chronic inflammatory environments. IFNγ is 
secreted by activated natural killer (NK) cells, iNKT, and Th1 cells and primes 
macrophages to become highly sensitive to TLR stimuli and increases their 
production of TNFα and interleukin-12 (IL-12).  Thus, IFNγ plays vital roles in 
cell-mediated immunity and host defense against intracellular pathogens. 
Interestingly, elevated levels of IFNγ and macrophage exhibiting an IFN signature 
are observed in rheumatoid arthritis and lupus individuals, suggesting a 
pathogenic role for IFNγ-dependent chronic macrophage activation25, 26.  
Although, the ability for IFNγ to enhance the inflammatory potential of TLR-
activated macrophages is a well-known phenomenon, how IFNγ affects the 
intrinsic regulation of macrophage activation remains to be determined. 
Here, we investigated the effect IFNγ has on TLR-activated macrophages 
and reveal that IFNγ sustains inflammatory macrophage activation by attenuating 
their sensitivity to extracellular adenosine.  Specifically, we demonstrate that IFNγ 
treatment selectively blocks the induction of the adenosine 2b receptor (A2bR).  
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We further show that IFNγ inhibition of LPS-induced A2bR prevents completion of 
an important negative feedback loop, thus rendering macrophages hyper-
inflammatory. Finally, we reveal the therapeutic potential of enhancing A2bR 
expression in macrophages to treat inflammatory disorders. In summation, our 
data illustrate the therapeutic potential of targeting macrophage-specific A2bR to 
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Materials and Methods 
 
Mice and macrophage isolation. C57BL/6 mice were purchased from the 
Charles River Laboratories. These studies were reviewed and approved by the 
University of Maryland Institutional Animal Care and Use Committee. Bone 
marrow-derived macrophages were prepared from 6-8 week old female C57BL/6 
as previously described 75 and differentiated in 20% L929 (LC14) conditioned 
media unless otherwise noted. RAW264.7 cells (TIB-71TM) were obtained from 
ATCC (Manassas, VA).  
 
Reagents. ATP and adenosine were purchased from Sigma-Aldrich (St. Louis, 
MO). Recombinant mouse IFNγ was purchased from R&D systems (Minneapolis, 
MN) and reconstituted according to the manufacture’s directions. Ultra Pure LPS 
E. coli K12 were purchased from InvivoGen (San Diego, CA). MRS1754, 
CGS21680, N-ethyl carboxamidoadenosine (NECA), and BAY 60-6583 were 
purchased from Tocris Bioscience (R&D Systems; Minneapolis, MN).  
 
Stimulation conditions. All in vitro experiments were performed at 1-2x106c/mL in 
tissue culture treated plates. Mouse macrophages studies were performed in 
DMEM/F12+GlutaMax (Gibco, Life Technologies, Grand Island, NY) supplemented 
with 10% FBS, 1% pen/strep, and 1% glutamine (Gibco, Life Technologies;, Grand 
Island, NY) unless otherwise indicated. For all experiments, macrophages were 
primed overnight with 100U/mL IFNγ followed by addition of 10ng/mL Ultra Pure 
LPS with or without 10µM ATP or adenosine unless indicated otherwise.  
 




Gene Expression Analysis. Total RNA was isolated by using TriZol (Invitrogen, 
Life Technologies;, Grand Island, NY) and converted to cDNA using the 
ThermoScript Kit (Invitrogen, , Life Technologies) according to the manufacture’s 
protocol. qPCR analysis was performed using a LightCycler 480 Real-Time PCR 
System (Roche Diagnostics Corporation-Roche Applied Science;, Indianapolis, IN) 
and GoTaq qPCR Master Mix (Promega;, Madison, WI). Primer pairs used to 
amplify specific gene products are listed in Table 1. Relative expression levels 
were calculated using the ΔΔCt method 6.  Gapdh was used as the housekeeping 
gene for normalization. 
 
Flow Cytometry Antibodies and Analysis. Anti-mouse CD16/32 was purchased 
from AnaSpec (Freemont, CA). Anti-mouse CD39-AF647 (24DMS1) was 
purchased from eBioscience (San Diego, CA). Anti-mouse F4/80-pacific blue 
(BM8) was purchased from BioLegend (San Diego, CA). Anti-mouse CD11b-FITC 
(M1/70) was purchased from BD Biosciences (San Jose, CA). Samples were 
analyzed on a BD FACSCanto (BD Biosciences). Data were analyzed using 
FlowJo software (Tree Star, Inc., Ashland, OR). 
 
Secreted Cytokine Detection. Cytokine production was determined by a 
sandwich ELISA using specific capture and biotinylated detection antibody pairs: 
anti-mouse TNF-purified (G281-2626), TNF-biotin (MP6-XT3), IL-12/23p40-purified 
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(C15.6), IL-12/23p40-biotin (C17.8), IL-10-purified (JES5-2A5), IL-10-biotin (JES5-
16E3). 
 
ATP Hydrolysis Assay. eATP hydrolysis was detected using the ATPlite 
Luminescence ATP Detection Assay System (PerkinElmer; Waltham, MA) 
according to the manufacture’s protocol omitting the cell-lysis step. 
 
Inorganic Phosphate Release Assay. Adenine nucleotide hydrolysis was 
detected using the BIOMOL Green Reagent (Enzo Life Sciences; Farmingdale, 
NY) according to the manufacture’s protocol.  
 
Primary Macrophage Transfection. BMDMs were transfected by nucleofection 
using the Amaxa Mouse Macrophage Nucleofector Kit (Lonza Cologne AG, 
Cologne, Germany) according to manufacture’s protocol. Briefly, 1×106 BMDMs 
were resuspended in 100µl of nucleofector solution (Lonza Cologne AG, Cologne, 
Germany) and nucleofection performed using the Nucleofector I Device, program 
Y-01. Cells were transfected with 3µg of pmaxGFP (Lonza Cologne AG, Cologne, 
Germany) alone or with pcDNA4/V5-His-A2b 105 (provided by Ravid, K.). The 
cytomegalovirus (CMV) promoter drives the expression of both cDNAs.  500µL of 
pre-warmed media containing was immediately added to the cuvette and cells 
transferred to tissue culture plates. Cells were allowed to recover overnight and 
media was replaced prior to stimulation.  
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Statistical Analysis. Data analysis was performed using GraphPad Prism 
software (GraphPad Software Inc.; La Jolla, CA) and analyzed using the 
Student’s t test. The statistical differences between groups, with the p-values are 











IFNγ  sustains inflammatory macrophage responses 
 
 The prototypical Th1-associated cytokine, IFNγ is known to promote 
classical macrophage activation.  To test whether IFNγ can influence the 
magnitude and duration of inflammatory cytokine production by TLR-activated 
macrophages, we exposed bone marrow-derived macrophages (BMDMs) to IFNγ 
overnight followed by subsequent exposure to the TLR4 ligand, LPS over time 
(Figure 1A).  Indeed, we found that macrophages treated with IFNγ significantly 
increased the total amount of TNFα produced by LPS-activated macrophages 
throughout the time of LPS exposure compared to macrophages stimulated with 
LPS alone.  We then examined whether IFNγ modulated the stability of an 
induced activated state in macrophages.  To do this, we stimulated unprimed or 
IFNγ primed macrophages with LPS.  After 2 hours, the LPS was removed and 
the macrophages were re-cultured in fresh LPS-free media and cytokine 
production was assessed 2 hours later.    
As we previously demonstrated 54, unprimed, LPS-stimulated 
macrophages significantly reduce TNFα production in response to the loss of 
activating stimuli from their culture environment (Figure 1B).  In contrast, IFNγ 
primed macrophages continued to secrete TNFα, with little reduction in the 
amount of TNFα produced, even once the LPS had been removed the 
macrophage cultures (Figure 1B).  Similar results were achieved with regard to 
IL-12p40 production (Figure 1C).  Collectively, these results suggest that TLR 
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stimulation promotes a short-lived inflammatory activation status in macrophages 
and that IFNγ blocks this inherent ability to self-regulate, thus rendering 




Figure 1. IFNγ prevents transient inflammatory activation, rendering macrophages hyper-
inflammatory. (A) Cytokine produced by LPS stimulated unprimed (black squares, solid line or 
IFNγ primed (gray circles, solid line) over time. TNFα was measured by ELISA. The means +/- 
SD of triplicates are shown and are representative of 3 independent experiments. (B,C) Unprimed 
(black bars) and IFNγ primed (gray bars) BMDMs were stimulated with LPS for 2-4 hr, then 
washed with PBS and replaced with LPS-free media and monitored over the next 2 hours for 
TNFα (B), IL-12/23p40 (C). Protein levels were measured by ELISA. The means +/- SD of 
triplicates are shown and are representative of 2 independent experiments. 
 
 
 79   
 
LPS-induced ATP release and hydrolysis is intact in the presence of IFNγ  
 
We recently demonstrated that in response to TLR stimulation, 
macrophages actively transition from an inflammatory to a regulatory activation 
status by actively releasing and converting extracellular ATP into anti-
inflammatory adenosine via CD39 54.   Because IFNγ treatment prevents the 
intrinsic development of regulatory macrophages upon exposure to TLR stimuli, 
we postulated that IFNγ might interfere an important component of this newly 
identified CD39-based autoregulatory mechanism in macrophages.  This 
signaling cascade is initiated by the release of intracellular stores of ATP by TLR-
activated macrophages into the extracellular space.  Accordingly, we assessed 
whether IFNγ treatment may modulate TLR-induced ATP release and observed 
negligible levels of eATP in the culture media of LPS stimulated BMDMs in the 
absence and presence of IFNγ  (data not shown).  These data were consistent 
with the prior observations that BMDMs express high levels of CD39, thus 
limiting the detection of eATP 54.  To more closely examine the effect IFNγ may 
have on eATP release, we stimulated RAW264.7 cells, which express low levels 
of CD39, thus permitting the ability to detect eATP released by macrophages 54.  
Although we could detect the presence of ATP released into the culture medium 
upon LPS stimulation, it was unchanged in the presence of IFNγ (Figure 2A). 
These data suggest that IFNγ does not substantially modulate CD39 levels in 
macrophages. 
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We next compared the level of CD39 expressed on the surface of 
macrophages exposed to LPS alone or following IFNγ treatment.  CD39 
remained highly expressed by macrophages regardless of culture conditions and 
was actually upregulated by IFNγ (Figure 2B).   Next, we examined the effect of 
IFNγ on ecto-ATPase activity and observed that similar rates of eATP hydrolysis 




Figure 2. LPS-induced ATP release and hydrolysis is intact in the presence of IFNγ. (A) 
Levels of ATP released from LPS-stimulated unprimed (black line) and IFNγ primed (gray line) 
RAW264.7 cells was measured over time. The means +/- SEM of 2 independent experiments are 
shown. (B) Analysis of CD39 surface expression (black histograms) on unprimed (left) and IFNγ 
primed (right) BMDMs compared to isotype controls (gray histograms). Data are representative of 
2 independent experiments. (C) The hydrolysis of 500µM ATP by unprimed BMDMs (black 
squares, solid line) over time compared to IFNγ primed BMDMs (gray circles, solid line). Percent 
of hydrolysis was compared to levels of ATP detected in the absence of cells and determined by 
the ATPlite assay. The means +/-SEM from 3 independent experiments is shown.  
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The functional consequence of CD39 activity is adenosine-mediated 
immunosuppression 54; therefore we next investigated if IFNγ make 
macrophages refractive to eATP-induced immunosuppression.  As we have 
previously shown, low levels of eATP potently suppresses LPS-induced TNFα 
and IL-12/23p40 production by unprimed macrophages (Figure 3A,B).  However, 
the attenuation of inflammatory cytokine secretion was completely abolished in 
the presence of IFNγ, thus indicating that IFNγ primed macrophages fail to readily 
transition to an immunoregulatory activation state in the presence of eATP 
(Figure 3A,B). Having shown that CD39 expression and activity are in tact in the 
presence of IFNγ, we next addressed whether IFNγ modulates macrophage 
responses to adenosine itself.   Indeed, adenosine significantly reduced the 
amount of TNFα and IL-12/23p40 secreted by macrophages stimulated with LPS 
alone and IFNγ treatment negated the immunosuppressive effect of adenosine, 
thus recapitulating the results observed by macrophages exposed to eATP 
(Figure 3C,D).  However, adenosine-mediated IL-10 production was unaffected 
by IFNγ treatment (Figure 3E). Together, these data indicate that the inability of 
IFNγ primed inflammatory macrophages to readily transition to an anti-
inflammatory state must occur downstream of eATP hydrolysis and is caused by 
a decreased ability to respond to adenosine. 
 
 




Figure 3. IFNγ blocks ATP-induced immunosuppression downstream of eATP hydrolysis. 
(A,B)  Unprimed (black bars) and IFNγ primed (gray bars) BMDMs were stimulated with LPS in 
the absence or presence of 10µM ATP for 8 hrs. TNFα (A) and IL-12/23p40 (B) production was 
measured by ELISA. The means +/- SEM from three independent experiments are shown. (C-E)  
Unprimed (black bars) and IFNγ primed (gray bars) BMDMs were stimulated with LPS in the 
absence or presence of 10µM adenosine for 8 hrs. TNFα (C), IL-12/23p40 (D), and IL-10 (E) 
production was measured by ELISA. The means +/- SEM from three independent experiments 
are shown.  
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IFNγ  inhibits LPS-induced A2bR expression in macrophages 
 
The plasticity of inflammatory macrophages relies on their ability to 
respond to eATP-derived adenosine; however it remains elusive whether IFNγ 
modulates the adenosine receptor expression profile of inflammatory 
macrophages.  Therefore we compared adenosine receptor expression of LPS 
activated macrophages under primed and IFNγ primed conditions.  In the 
absence of IFNγ, LPS dramatically upregulated A2bR transcript levels compared 
to naïve macrophages (Figure 4A).  Moreover, expression of the other adenosine 
receptors decreased upon exposure to LPS.  Interestingly however, the induction 
of the A2bR by LPS was severely inhibited by IFNγ (Figure 4A).  In addition, IFNγ 
appears to specifically limit the A2bR expression in inflammatory macrophages, 
as it was the only adenosine receptor to be downregulated by IFNγ treatment.  
Moreover, IFNγ completely inhibited the induction of the A2bR for the first hour of 
LPS stimulation, while unprimed macrophages significantly increased transcript 
levels of the A2bR (Figure 4B).  Furthermore, IFNγ primed macrophages 
continuously expressed low levels of A2bR transcript and protein regardless of 
time exposed to LPS (Figure 4B,C).  Collectively, these data indicate that IFNγ 
stably decreases the ability for macrophages to sense extracellular adenosine.  
 
 




Figure 4. IFNγ inhibits LPS-induced A2bR expression in macrophages (A) mRNA expression 
of A1r (dotted bars), A2ar (horizontally striped bars), A2br (diagonally striped bars), and A3r (solid 
black bars) in unprimed and IFNγ primed BMDMs stimulated with LPS over time.  The means +/- 
SD of duplicates are shown and are representative of 3 independent experiments.  (B) Unprimed 
BMDMs (black bars) and IFNγ primed BMDMs (gray bars) were stimulated with LPS over time. 
A2bR mRNA levels were determined by qPCR. The means +/-SD of triplicate determinations are 
shown and are representative of 2 independent experiments. (C) Protein expression of the A2bR 
was determined by Western Blot. Unprimed (-) and IFNγ primed (+) BMDMs were stimulated over 
time with LPS.  GAPDH was probed for loading control.  Data are representative of 2 independent 
experiments. 
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IFNγ  inhibits A2bR-dependent immunosuppression 
   
Because LPS-induced adenosine generation represents an important 
negative feedback loop controlling inflammatory activation responses in 
macrophages, we hypothesized that IFNγ may specifically inhibit the induction of 
the A2bR in order to maintain an inflammatory activation state. To address the 
functional significance of the A2bR during inflammatory macrophage activation 
we primed macrophages with an A2bR-specific antagonist, MRS1754, and then 
exposed the cells to LPS in the presence or absence of adenosine.  Unprimed 
macrophages were highly sensitive to adenosine and exhibited marked reduction 
in LPS-induced TNFα and IL-12/23p40 production compared to macrophages 
stimulated with LPS alone (Figure 5A,B).  The effect of adenosine was 
completely dependent on the A2bR as macrophages primed with MRS1754, an 
A2bR-specific antagonist, demonstrated no significant difference in TNFα or IL-
12/23p40 levels regardless of adenosine being present in their extracellular 
milieu (Figure 5A,B).  Thus, these results suggest that specific A2bR antagonism 
recapitulates the inhibitory effects of IFNγ treatment.  Adenosine potently 
suppressed LPS-induced TNFα in a dose-dependent manner in unprimed cells, 
indicating that in the absence of priming macrophages are highly sensitive to low 
levels of extracellular adenosine (Figure 5C).  MRS1754 treatment completely 
recapitulated the inhibitory effect induced by IFNγ, thus further demonstrating that 
IFNγ impairs adenosine-mediated immunosuppression via blocking A2bR 
signaling.  
 




Figure 5. IFNγ inhibits A2bR-dependent immunosuppression in macrophages. (A,B)  
Unprimed (black bars) and MRS1754 primed (gray striped bars) BMDMs were stimulated with 
LPS in the absence or presence of 10mM adenosine for 8 hrs. TNFα (A), IL-12/23p40 (B) 
production was measured by ELISA. The means +/- SEM from at least three independent 
experiments are shown. (C) Unprimed (black squares, solid line), IFNγ primed (gray circles,solid 
line), and MRS1754 primed (gray open squares, dotted line) BMDMs were stimulated with LPS in 
the presence or absence of adenosine at various concentrations.  8 hrs. post stimulation, TNFα 
levels were detected by ELISA. Percent of TNFα produced is based on TNFα levels produced by 
LPS alone for each condition. The means +/-SEM from at least 3 independent experiments are 
shown. (D,E)  Unprimed (black bars) and IFNγ primed (gray bars) BMDMs were stimulated with 
LPS in the absence or presence of 1nM of the A2bR-specific agonist NECA (D) or BAY 60-6583 
(E). TNFα production was measured 8 hrs. after stimulation by ELISA. Percent of TNFα produced 
is based on TNFα levels produced by LPS alone for each condition. The means +/- SEM from 
three independent experiments are shown.  (F) Unprimed (black line) and IFNγ primed (gray line) 
BMDMs were stimulated with LPS in the absence or presence of the A2aR-specific agonist, CGS 
21680 at various concentrations. TNFα levels were detected 8 hrs. after stimulation by ELISA. 
Percent of TNFα produced is based on TNFα levels produced by LPS alone for each condition.  
The means +/- SD from triplicate determinations are shown and is representative of 2 
independent experiments.  
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Having shown that IFNγ prevents the induction of LPS-induced A2bR 
expression, we next addressed whether IFNγ blockade of A2bR was responsible 
for sustaining inflammatory macrophage responses in the presence of 
adenosine.   Macrophages can express all four known adenosine receptors to 
some degree, thus the specific contribution of the A2bR in regulating 
macrophage responses may be masked since adenosine is a ligand for these 
four receptors.  Therefore, we further examined the role of A2bR-dependent 
signaling in inflammatory macrophages exposed to the A2bR-specific agonists, 
NECA or BAY 60-6583.   Unprimed macrophages stimulated with LPS and either 
A2bR agonist resulted in a 70-80% reduction in TNFα secreted, compared to 
macrophages exposed to LPS alone (Figure 5D,E).  Macrophages treated with 
IFNγ; however, largely retained their ability to secrete high levels of TNFα even in 
the presence of NECA or BAY 60-6583 compared to their unprimed counterparts.  
Moreover, we investigated whether the A2bR is the dominant adenosine receptor 
that suppresses inflammatory cytokine production by exposing macrophages to 
LPS in the presence of the closely related adenosine mimetic, CGS 21680, which 
preferentially stimulates the A2aR.  Interestingly, we observed that TNFα levels 
remained unchanged upon addition of CGS21680 and that IFNγ treatment did not 
modulate A2aR-specific responses (Figure 5F), thereby suggesting that the 
A2aR is not a major adenosine receptor involved in the suppression of TNFα. 
Together, these data indicate that IFNγ specifically hinders the induction of the 
A2bR, the major adenosine receptor responsible for auto-regulating inflammatory 
cytokine production in TLR-stimulated macrophages.  
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A2bR overexpression permits the development of immunosuppressive 
macrophage in the presence of IFNγ   
 
 Having identified that IFNγ specifically prevents the induction of A2bR 
expression to maintain a hyper-inflammatory activation status in macrophages, 
we wished to explore whether IFNγ-dependent inhibition of A2bR expression was 
directly responsible for halting the development of immunoregulatory 
macrophages. To do this, we overexpressed the A2bR in BMDMs by transfection 
along with a GFP-containing plasmid to readily track transfection efficiency. After 
24 hours, we assessed transfection efficiency and confirmed that the A2bR was 
overexpressed in co-transfected BMDMs (Figure 6A,B).  We then exposed these 
cells to IFNγ followed by stimulation with LPS in the presence or absence of 
adenosine and monitored TNFα production.  Despite the presence of IFNγ, 
macrophages over-expressing the A2bR secreted 20% less TNFα compared to 
macrophage transfected with the GFP containing plasmid alone (Figure 6C). 
These results preliminarily demonstrate that IFNγ renders macrophages hyper-
inflammatory by specifically downregulating the A2bR.  Together, these data 
reveal that IFNγ interferes with the autoregulation of macrophages following TLR 
activation by specifically attenuating A2bR-mediated responses, thus resulting in 
exacerbated inflammatory macrophage responses.  
  
 






Figure 6. A2bR overexpression permits the development of immunosuppressive 
macrophages in the presence of IFNγ . (A,B) BMDMs were co-transfected with plasmids 
containing GFP and A2bR cDNA. After 24 hrs., transfection efficiency were assessed by 
immunofluorescence microscopy (A) and probed for A2bR-V5 expression by Western Blot (B). 
Data are representative of 2 independent experiments. (C) BMDMs trasnfected with pGFP alone 
(black bars) or co-transfected with pA2bR (black striped bars) were primed with IFNγ  and 
stimulated with LPS in the presence or absence of 10µM adenosine. TNFα production was 
measured 8 hrs. after stimulation by ELISA. Percent of TNFα produced is based on TNFα levels 
produced by LPS alone for each condition. Data are preliminary and from 1 determination per 
condition.  
 




Although inflammatory macrophage activation is a necessary component 
of host defense, if left uncontrolled, it can lead to severe tissue damage, organ 
failure and even death.  Indeed, previous observations suggest that transient 
macrophage activation is integral to survival of the host14, 54, 106. The inability for 
macrophages to control their activation state has been suggested to support the 
pathogenesis of an extensive list of chronic inflammatory diseases including 
inflammatory bowel disease, lupus, and rheumatoid arthritis 25, 107. However, the 
molecular mechanisms preventing transient inflammatory macrophage activation 
under these conditions remain incompletely understood.  Herein, we reveal a 
novel mechanism supporting IFNγ-mediated induction of chronic inflammatory 
macrophages and demonstrate that IFNγ actively desensitizes macrophages to 
immunosuppressive adenosine thereby sustaining inflammatory responses.  
The novelty of this work is the demonstration that IFNγ represents the first 
known physiological inhibitor of the purinergic-dependent auto-regulation of 
inflammatory macrophages.  We previously demonstrated that pharmacological 
inhibition or genetic deletion of the ecto-ATPase, CD39 renders macrophage 
hyper-inflammatory due to the inability to convert extracellular ATP into 
adenosine.  Here, we reveal that blockade of adenosine-mediated effects can 
occur in response to IFNγ, which blocks the inherent ability for inflammatory 
macrophages to transition towards an adenosine-dependent immunosuppressive 
state by preventing A2bR signaling (Figure 7).  
 
 




Figure 7. A new model of IFNγ-mediated chronic inflammatory activation in macrophages. 
(1.) In response to LPS activation alone, inflammatory cytokine production is transient and 
dependent on the inherent ability for macrophages to convert extracellular ATP into 
immunosuppressive adenosine. (2.) Within the first hours of exposure to LPS, macrophages 
selectively upregulate the A2bR (blue) to increase sensitivity to newly generated adenosine levels 
rising within their extracellular space. (3.) The A2bR potently inhibits LPS-induced TNFα; IL-12 
production, thereby transitioning the macrophages towards an immunoregulatory state. (4.) 
Despite this auto-regulatory mechanism, chronic inflammatory macrophages can persist. This 
model illustrates that while IFNγ treatment does not interfere with CD39 (red) and CD73 (black) 
activity (boxed check marks), IFNγ severely inhibits the induction of the LPS-induced A2bR 
(boxed ‘X’).  Thus, IFNγ is able to sustain TLR-induced TNFα;IL-12 production promoting hyper-
inflammatory macrophage responses, which are prevalent in a variety of chronic diseases.  
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Although the anti-inflammatory effect of adenosine on macrophages is 
well known, the intracellular mechanisms supporting its action remains unclear.  
Here, we demonstrate that the A2bR is the dominant adenosine receptor 
employed by TLR-activated macrophages to limit TNFα and IL-12/23p40 
production.  The elegant work by Ivashkiv and colleagues has demonstrated a 
role for STAT3-dependent inhibition of STAT1 indicating that IL-10-induced 
STAT3 may repress IFN/STAT1 activity 26, 108, 109.   However, in our studies 
ATP/adenosine-induced IL-10 production was minimally affected by IFNγ 
treatment.  Thus, while it is known that IFNγ can antagonize IL-10-depedent 
suppression of TLR-induced TNFα and IL-12/23p40, the failure for IFNγ to 
suppress these inflammatory cytokines suggests a mechanism independent of 
IL-10 signaling that is largely responsible for induction of a hyper-inflammatory 
macrophage activation status.  
All adenosine receptors are GPCRs, however only the A2aR and A2bR 
are coupled to Gαs, thus inducing the generation of intracellular cAMP upon 
stimulation.  We have previously demonstrated that cAMP can drive the 
development of anti-inflammatory macrophages7.  Because of the relatively lower 
affinity of the A2bR to adenosine compared to the A2aR, it has also been 
proposed that the A2bR may be preferentially employed by cells during 
pathophysiological diseases when extracellular adenosine levels increase 10-100 
fold above homeostatic conditions.  Indeed, our work demonstrating the selective 
upregulation of the A2bR by LPS is consistent with other reports showing that 
inflammatory TNFα and hypoxia induce the A2bR 93, 105, 110, thus these data 
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collectively support a particular role for the A2bR in mediating a negative 
feedback loop to prevent overactive inflammation. 
Despite our observations regarding adenosine receptor induction in a 
variety of inflammatory scenarios, how the A2bR is regulated at the 
transcriptional level remains poorly understood.  Our current study expands our 
understanding of A2bR regulation under inflammatory conditions and shows for 
the first time that IFNγ directly inhibits the development of regulatory 
macrophages following TLR activation via inhibiting the transcription of A2bR.  It 
is interesting that we observed increased A2br levels in macrophages exposed to 
LPS and ATP or adenosine, suggesting that adenosine signaling itself may 
positively regulate the expression of the A2bR.  Hif1α has been implicated in the 
transcriptional regulation of the A2bR in endothelial cells under hypoxic 
conditions; however, we found that macrophages stimulated with LPS in the 
presence of a HIF1 stabilizer (DMOG)111 did not enhance A2br levels (data not 
shown).  Thus, the transcriptional regulation of the A2br may be differentially 
regulated depending on the tissue environment and the presence of TLR ligands.  
Interestingly, we found putative cAMP response element binding (CREB), γ-
activated sequence (GAS), and specificity protein 1 (Sp1) binding sites in close 
proximity to the transcriptional start site of A2br (Figure 8).  Both CREB and Sp1 
have been shown to play roles in the induction of many regulatory macrophage-
associated genes including, HB-EGF and IL-10 7, 109.  Thus, it is interesting to 
speculate that the A2bR may be included as a novel genetic marker of 
immunosuppressive macrophages.   
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Figure 8. Schematic representation of transcription factor binding sites within the 
promoter region of mouse A2br. Location of putative transcription factor DNA binding sites was 
determined manually based on established consensus core sequences recognized by 
transcription factors. Of the major transcription factors implicated in macrophage responses, 
putative binding sites for CREB, GAS, and Sp1 were found within 300bp of the transcriptional 
start site (TSS).  
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This work suggests a therapeutic potential of over-expressing the A2bR in 
macrophages to circumvent IFNγ pro-inflammatory signaling.  These data 
suggest for the first time that targeting the A2bR specifically on macrophages 
may represent a novel strategy to treat chronic inflammatory diseases.  It will be 
valuable to assess the impact of macrophage-A2bR over-expression in vivo.  
High TNFα and IFNγ levels often accompany chronic inflammatory disorders112. 
Moreover, extracellular adenosine levels have been demonstrated to increase 
100 fold during chronic inflammatory conditions such as rheumatoid arthritis49.    
Thus, our results showing that CD39 activity is intact in the presence of IFNγ, is 
consistent with these observations.  Here, we show that IFNγ potentiates the 
release of these inflammatory cytokines from macrophages by blocking induction 
of the anti-inflammatory receptor, A2bR.  In this study we demonstrate that 
preserving or over-expressing the A2bR in macrophages may rescue the anti-
inflammatory phenotype of macrophages exposed to IFNγ. Thus targeting A2bRs 
on macrophages may enhance our current arsenal of treatment options for 
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Chapter 4: Exploitation of the adenosine 2a receptor promotes 

















































From: Cohen, HB, and Mosser, DM. “Exploitation of the adenosine 2a receptor 
promotes L.major survival within macrophages”. Manuscript in preparation for 
submission. 2014. 
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Introduction 
Cutaneous leishmaniasis is a parasitic disease that exemplifies the 
importance of properly regulated macrophage responses. Infected individuals 
often suffer from debilitating lesions at the infection site that arise when the body 
fails to clear parasites before repairing the infected tissue.   The World Health 
Organization estimates that 1-2 million individuals annually contract 
Leishmaniasis and there are few treatment options available to alleviate the 
disease34.  
Individuals contract the disease when an infected sand fly takes a blood 
meal, whereby the promastigote form of Leishmania major (L.major) is 
transmitted from the sand fly into the blood of the host. Promastigotes are rapidly 
taken up by professional phagocytic cells, and transform into the intracellular 
amastigote form.  Macrophages are the primary host cells in which these reside.  
Thus, understanding how macrophage anti-microbial activity is regulated during 
infection is key to enhancing our understanding of the pathogenesis of cutaneous 
Leishmaniasis and the development of more effective therapeutics for this 
disease.  
Successful host defense against this intracellular parasite involves the 
generation of IFNγ.  This results in the generation of classically activated 
macrophages, which are defined by their ability to kill this and other intracellular 
pathogens 1. Classically activated macrophages (also known as M1) develop 
within environments rich in Th1-associated cytokines such as IFNγ and upon 
sensing pathogenic molecules via toll-like receptors (TLRs).  Upon IFNγ/TLR 
stimulation, macrophages produce high amounts of inflammatory cytokines 
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including TNFα and IL-12, which enhance the recruitment of immune cells to the 
site of infection to help clear the pathogen from the host. In addition, 
macrophages can produce nitric oxide (NO), which is toxic to intracellular 
pathogens.  Alternatively, macrophages can also play an important role in 
maintaining tissue homeostasis by assuming a regulatory phenotype. The 
production of pro-inflammatory mediators and anti-microbial activity is reduced 
and the secretion of anti-inflammatory IL-10 is increased in regulatory 
macrophages.  L. major infection persists in part due to the inability of 
macrophages to maintain an anti-microbial activation status, thus 
immunosuppressive macrophages ensue to the detriment of the host 35.  Despite 
the evidence to suggest roles for regulatory macrophages and IL-10 in this 
disease 9, 39, there are significant gaps in our understanding of how L.major 
inhibits classical macrophage activation and evades the host innate immune 
response. 
Extracellular adenosine triphosphate (eATP) and its degradation product, 
adenosine, have recently emerged as important modulators of innate immune 
responses 53. High levels of eATP (millimolar) acts as a ‘danger signal’ to warn 
the body of infection largely by activating the P2X7 receptor, which stimulates the 
coordination of an active NLRP3 inflammsome complex and subsequent 
secretion of IL-1β, which further potentiates neutrophil recruitment and warns the 
body of infection.  Paradoxically, we recently revealed that low levels of eATP 
(sub-millimolar) can render macrophages immunosuppressive due to their 
inherent ability to readily generate anti-inflammatory adenosine 54.  Macrophages 
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are equipped with the ecto-enzymes necessary to convert eATP into adenosine 
as well as the adenosine receptors required to mediate the transition from an 
inflammatory to regulatory macrophage. Thus, the balance between eATP and 
adenosine appears to be an important regulator of the inflammatory process.  
Although, stimulating adenosine receptors has been shown to improve non-
infectious inflammatory diseases and wound healing responses 53, 74, 90, 113, our 
understanding of how eATP hydrolysis and adenosine signaling is regulated 
during infection remains poorly understood.  In this study, we demonstrate that 
adenosine potently inhibits nitric oxide production by macrophages during L. 
major infection and that these cells also exhibit enhanced susceptibility to 
intracellular parasite growth.  We further show that during infection, macrophages 
preferentially upregulate the adenosine 2a receptor (A2aR) and that this 
adenosine receptor is the dominant adenosine receptor suppressing anti-
microbial activity in macrophages.  The results from this study suggest that 
macrophage-A2aR may be a promising new target to effectively treat 
Leishmaniasis. 
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Materials and Methods 
 
Mice and macrophage isolation. Balb/c mice were purchased from the Charles 
River Laboratories. These studies were reviewed and approved by the University 
of Maryland Institutional Animal Care and Use Committee. Bone marrow-derived 
macrophages were prepared from 6-8 week old female Balb/c mice as previously 
described 75  and differentiated in 20% L929 (LC14) conditioned media unless 
otherwise noted.  
 
Parasites. L. major (WHO MHOM/IL/80/Friedlin) were isolated from infected 
BALB/c mice and grown as previously described. 8 Briefly parasites were grown 
in medium containing equal parts Schneider’s insect medium (Sigma-Aldrich, St. 
Louis, MO) and M-199 (Invitrogen, Rockville, MD) supplemented with 20% FBS, 
100 U/ml of penicillin, 100 µg/ml of streptomycin, and 2 mM glutamine. 
Metacyclic promastigotes were obtained as previously described 114 and used for 
all killing experiments.  Briefly, stationary phase parasites were washed three 
times with DPBS at 3500 RPM for 15 minutes.  The pellet was resuspended in 
PBS and counted via hemacytometer.  
 
Reagents. ATP, adenosine, and N6,2-O-dibutyryladenosine 3,5-cyclic adenosine 
monophosphate (dbcAMP) were purchased from Sigma-Aldrich (St. Louis, MO). 
Recombinant mouse IFNγ and IL-1β was purchased from R&D systems 
(Minneapolis, MN) and reconstituted according to the manufacture’s directions. 
Ultra Pure LPS E. coli K12 were purchased from InvivoGen (San Diego, CA). 
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POM-1 and CGS21680 were purchased from Tocris Bioscience (R&D Systems; 
Minneapolis, MN).  
Stimulation conditions. All in vitro experiments were performed at 1-2x106 
cells/mL in tissue culture treated plates. Mouse macrophages studies were 
performed in DMEM/F12+GlutaMax (Gibco, Life Technologies;, Grand Island, NY) 
supplemented with 10% FBS, 1% pen/strep, and 1% glutamine (Gibco, Life 
Technologies;, Grand Island, NY) unless otherwise indicated. For all experiments, 
macrophages were primed overnight with 100U/mL IFNγ followed by addition of 
10ng/mL Ultra Pure LPS with or without 100µM ATP or adenosine unless indicated 
otherwise. All L.major infections were performed on glass coverslips within wells of 
a 48-well culture plate at a multiplicity of infection (MOI) of 5:1 in the presence of 
3% C5d-deficient serum.  Infected cells were cultured for 2 hours at 37ºC+5%CO2, 
washed thoroughly to remove any unbound parasites and then re-cultured in the 
absence of free parasites for 24-48 hours.   
 
Gene Expression Analysis. Stimulations were performed in 1mL.  Total RNA was 
isolated by using TriZol (Invitrogen, Life Technologies;, Grand Island, NY) and 
converted to cDNA using the ThermoScript Kit (Invitrogen, , Life Technologies) 
according to the manufacture’s protocol. qPCR analysis was performed using a 
LightCycler 480 Real-Time PCR System (Roche Diagnostics Corporation-Roche 
Applied Science;, Indianapolis, IN) and GoTaq qPCR Master Mix (Promega;, 
Madison, WI). Primer pairs used to amplify specific gene products are listed in 
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Table 1. Relative expression levels were calculated using the ΔΔCt method 6.  
Gapdh was used as the housekeeping gene for normalization. 
 
Flow Cytometry Antibodies and Analysis. Anti-mouse CD16/32 was purchased 
from AnaSpec (Freemont, CA). Anti-mouse CD39-AF647 (24DMS1) was 
purchased from eBioscience (San Diego, CA). Anti-mouse F4/80-pacific blue 
(BM8) was purchased from BioLegend (San Diego, CA). Anti-mouse CD73-PE 
was purchased from BD Biosciences (San Jose, CA). Samples were analyzed on a 
BD FACSCanto (BD Biosciences). Data were analyzed using FlowJo software 
(Tree Star, Inc., Ashland, OR). 
 
Inorganic Phosphate Release Assay. Adenine nucleotide hydrolysis was 
detected using the BIOMOL Green Reagent (Enzo Life Sciences; Farmingdale, 
NY) according to the manufacture’s protocol.  
 
Microscopy and Immunofluorescence. To stain parasites by 
immunofluorescence, 5% anti-L. major immune serum from BALB/c mice was 
added to the monolayers for 20 min followed by FITC goat anti-mouse IgG 
(eBioscience) for 30 min. The nuclei were counterstained for 1 min with DAPI.  
Slides were examined using a Carl Zeiss Inverted Fluorescence Microscope 
(Axio Observer Inverted Microscope, Carl Zeiss SMT AG, Germany). Acquired 
images were used to count the number of parasites per cells and the number of 
infected cells.  
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Nitrite Detection Assay. NO production was estimated from the accumulation of 
NO2- in the medium after 24 h of macrophage activation using the Greiss reagent, 
as described previously 6. Briefly, equal volumes of culture supernatant and Greiss 
reagent were mixed for 10 min at room temperature. Absorbance at 540nm was 
measured with a Labsystems Multiscan Ascent assay plate reader. A solution of 
Na NO2- was used to construct a standard curve.  
 
Statistical Analysis. Data analysis was performed using GraphPad Prism 
software (GraphPad Software Inc.; La Jolla, CA) and analyzed using the 
Student’s t test. The statistical differences between groups, with the p-values are 












eATP-induced IL-1β minimally influences macrophage NO production 
 
 The role of eATP on macrophages during infectious disease is elusive 
and further complicated due to its differing role depending on its level of 
bioavailability.  Inflammatory macrophages that briefly encounter high levels of 
ATP (>1mM) secrete elevated amounts of IL-1β (Figure 1A). We recently 
demonstrated that macrophages highly express the ecto-ATPase, CD39, and 
can rapidly hydrolyze eATP 54.  Indeed, exposing inflammatory macrophages to 
eATP in the presence of the CD39-specific inhibitor, POM-1, permitted the 
production of IL-1β at sub-millimolar concentrations of eATP (Figure 1B). These 
data support previous reports suggesting a role for CD39 in the control of P2X7-
induced IL-1β responses 64.  The role of IL-1β in promoting inflammation, 
neutrophil recruitment and Th17 differentiation is well-documented 61, 115; however 
the role of eATP-induced IL-1β in regulating macrophage-intrinsic host defense 
mechanisms is unclear.  
The production of reactive nitrogen species (RNS) is toxic to intracellular 
pathogens and plays an integral part in limiting parasite survival within 
macrophages. To investigate whether IL-1β affects NO production, we performed 
a Griess assay on supernatants collected from macrophages primed with IFNγ 
overnight, followed by a 24-hour stimulation with LPS in the absence or presence 
of rIL-1β.  We observed a significant, but minimal effect of rIL-1β on nitrite 
production compared to IFNγ treatment alone; however rIL-1β did not further 
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enhance NO production by macrophages stimulated in the presence of LPS 
(Figure 1C).  Moreover, the ability for macrophages to control intracellular 
L.major was unchanged in the presence of rIL-1β (Figure 1D), thus suggesting 
that ATP-induced IL-1β does not act in an autocrine manner to further modulate 
anti-microbial responses in macrophages. Thus, high levels of eATP may play a 
more impactful role orchestrating cellular immunity than regulating macrophage-
intrsinic anti-microbial programs. Together, these observations further strengthen 
previous work indicating that under normal conditions, macrophages are 
equipped to readily metabolize eATP to limit inflammation 54.  However, whether 
low levels of eATP contribute to the susceptibility of macrophages to intracellular 
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Figure 1. eATP-induced IL-1β minimally influences macrophage NO production. (A,B) LPS 
primed BMDMs were stimulated for with various concentrations of ATP in the absence (A) or 
presence (B) of 10µM POM-1. IL-1β production was detected by ELISA. The means +/- SD of 
triplicates are shown and are representative of 3 independent experiments. (C) BMDMs were 
primed with IFNγ alone or stimulated with 5ng/mL rIL-1β and/or LPS for 24 hrs.  Nitrite production 
was determined by Griess assay. The means +/- SD of triplicates are shown and are 
representative of 2 independent experiments. (D) BMDMs were primed with IFNγ alone or 
stimulated with 5ng/mL rIL-1β and/or LPS at the time of L. major infection. Representative images 
are shown of parasites (green) within macrophages (blue) 48 hrs post infection. 
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CD39 activity attenuates nitric oxide production by macrophages  
 
We next examined the potential for IFNγ/LPS-stimulated macrophages to 
secrete nitrite in the presence of low levels of eATP (100µM) by Griess assay.  
We observed ~40% decrease in nitrite production from macrophages exposed to 
eATP compared to IFNγ/LPS-stimulated macrophages alone (Figure 2A).  
Moreover, this attenuation was completely reversed in the presence of POM-1 
suggesting that CD39-mediated eATP hydrolysis negatively influences NO 
production by macrophages.  To investigate the functional consequence of this, 
we primed macrophages with IFNγ overnight and then exposed macrophages to 
LPS and L.major in the presence or absence of 100µM ATP for 48 hours.  The 
survival of intracellular parasites positively correlated with the NO data indicating 
that inhibition of NO by eATP can prevent effective anti-microbial responses in 
macrophages.  Importantly, the ability for inflammatory macrophages to kill 
L.major was restored in the presence of POM-1 (Figure 2B).  Together, these 
data suggest that in addition to its role in limiting inflammatory cytokine 
production, CD39-mediated ATP hydrolysis promotes L.major survival within 
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Figure 2. CD39 activity inhibits NO production and enhances L.major survival in 
macrophages. (A) BMDMs were primed with IFNγ and stimulated with LPS in the absence or 
presence of 100µM ATP and/or 10µM POM-1 for 24 hrs. Nitrite production was determined by 
Griess assay. The means +/- SD of triplicates are shown and are representative of 2 independent 
experiments. (B) BMDMs were primed with IFNγ and stimulated with LPS in the presence or 
absence of 100µM ATP and/or 10µM POM-1 at the time of L.major infection. Representative 
images are shown of parasites (green) within macrophages (blue) 48 hrs post infection. 
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Macrophage ecto-enzyme activity is intact during infection 
 
Leishmania are obligate intracellular pathogens that lack the ability to 
synthesize adenosine de novo. Therefore, the parasite must acquire adenosine 
from the mammalian environment for its survival.  Therefore, we investigated 
whether L.major modulated the ability of macrophages to convert eATP into 
adenosine by stimulating macrophages with IFNγ/LPS in the absence or 
presence of L.major.  eATP hydrolysis is controlled by CD39, which 
dephosphorylates ATP and ADP into AMP and CD73 is an AMP-specific 5’-
ectonucleotidase that removes the phosphate group to yield adenosine.  At 24 
hours post infection, we evaluated CD39 and CD73 expression and activity to 
investigate whether L.major modulated the macrophage-mediated eATP 
hydrolysis.  Macrophage CD39 expression and activity remained unchanged 
(Figure 3A,B).  Similarly, CD73 activity was not affected by infection, despite the 
slight downregulation of CD73 expressed on the surface of macrophages during 
infection (Figure 3B,C). L.major infection resulted in no significant modulation in 
eATPase or eAMPase activity (Figure 3B,D).  Together, these data indicate that 
although CD39-mediated ATP hydrolysis renders macrophages susceptible to 
L.major infection, CD39 and CD73 are not specifically targeted by the parasite as 
a means to evade host anti-microbial responses.  
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Figure 3. Macrophage CD39 and CD73 activity are intact during L.major infection. (A,C) 
Analysis of CD39 (A) and CD73 (C) surface expression on naïve (left) and IFNγ/LPS treated 
BMDMS (right) in the absence (solid black histograms) or presence of L.major (dotted black 
histograms) compared to isotype controls (gray histograms). Data are representative of 2 
experiments.  (B,D) The hydrolysis of 500µM ATP (B) or AMP (D) by BMDMs in treated in the 
presence or absence of IFNγ/LPS and/or during L.major infection.  Hydrolysis was measured 1 hr 
after exposure to extracellular nucleotides and was measured by the inorganic phosphate (Pi) 
release assay. The mean +/-SD from triplicate determinations is shown and is representative of 2 
independent experiments.  
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Extracellular adenosine inhibits NO production in classically activated 
macrophages   
 
Having shown that CD39-mediated eATP hydrolysis renders 
macrophages susceptible to L.major infection without any substantial change in 
CD39 expression or activity during infection, we then hypothesized that L.major 
may alter the sensitivity of macrophages to respond to ATP-derived adenosine.  
We previously identified that adenosine was the major metabolite generated from 
ATP hydrolysis, which mediated the immunosuppressive effects observed from 
inflammatory macrophages exposed to low levels of eATP 54.  To demonstrate 
whether adenosine affects NO production, we stimulated IFNγ primed 
macrophages with LPS and increasing concentrations of adenosine.  Indeed, 
adenosine inhibited nitrite production in a dose-dependent manner (Figure 4A).  
Interestingly, adenosine decreased nitrite levels by ~40%, thus recapitulating 
results observed with inflammatory macrophages exposed to ATP (Figure 2). 
IFNγ primes macrophages to effectively thwart intracellular pathogens and upon 
TLR stimulation are subsequently able to produce copious amount of NO.  
Indeed, macrophages treated with IFNγ/LPS effectively kill intracellular parasites 
compared to naïve macrophages as evidenced by the lack of parasites found 
within these macrophages 48 hours post infection (Figure 4B,C).  However, anti-
microbial activity by IFNγ/LPS treated macrophages was largely blocked by the 
addition of extracellular adenosine at the time of infection (Figure 4B,C).  These 
results suggest that extracellular adenosine promotes L.major intracellular growth 
by inhibiting NO production in macrophages.  
 




Figure 4. Extracellular adenosine inhibits NO production in classically activated 
macrophages. (A) BMDMs were primed with IFNγ and stimulated with LPS in the absence or 
presence of various adenosine concentrations for 24 hrs.  Nitrite production was determined by 
Griess assay. The means +/- SD of triplicates are shown and are representative of 2 independent 
experiments. (B,C) BMDMs were infected with L.major in the absence (naïve) or presence of 
IFNγ/LPS +/- 100µM adenosine.  48 hrs later, parasite survival was quantified within 100 BMDMs 
via fluorescence microscopy (B). The means +/- SD of triplicates are shown and are 
representative of 2 independent experiments.  Representative images are shown of parasites 
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A2aR expression is upregulated during L.major infection in macrophages 
There are four known adenosine receptors: A1R, A2aR, A2bR, and A3R.  
All of which can be expressed by macrophages, with the A2aR being most highly 
expressed on naïve cells (Figure 5A).  While it has been demonstrated that 
inflammatory stimuli such as LPS and TNFα preferentially upregulates the A2bR 
to enhance sensitivity to immunosuppressive adenosine 54, 93, it remains 
unknown whether the expression of these receptors are influenced during 
parasitic infection. In fact, L.major significantly enhanced the expression of the 
A2ar, A2br and A3r transcripts compared to naïve, uninfected cells (Figure 5B).  
It is interesting to note, L.major alone was able to enhance expression of the 
A2br.  However, A2br levels were diminished in infected macrophages in the 
presence of IFNγ (Figure 5C). Surprisingly, however, the upregulation of the 
A2aR by L.major remained elevated even in the presence of IFNγ (Figure 5C).  
Similar results were observed at the protein level such that macrophages 
infected with L.major expressed greater levels of the A2aR on their surface 
(Figure 5D). Thus, these results suggest that in the presence of L.major, 
macrophages selectively augment adenosine receptor expression to enhance 

































Figure 5. L.major upregulates A2aR expression in macrophages. (A,B) Adenosine receptor 
mRNA expression in naïve (A) and IFNγ/LPS (B) stimulated BMDMs in the absence (dark bars) 
or presence (light bars) of L.major  at 24 hrs post-infection.  Transcript levels were determined by 
qPCR and normalized to Gapdh expression for each condition. The means +/- SD of triplicates 
are shown and are representative of 3 independent experiments. (C) Analysis of A2aR surface 
expression on IFNγ/LPS stimulated cells alone or infected with L.major.  48 hrs post stimulation, 
A2aR levels were measured by FACS on F4/80+ cells. The means +/-SD are shown and are 
representative of 3 independent experiments.  
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A2aR signaling attenuates NO production in activated macrophages 
 
All adenosine receptors are G-protein coupled receptors (GPCRs); 
however only the A2aR and A2bRs are coupled to the Gαs and capable of 
increasing intracellular cAMP levels.  We previously showed that macrophages 
exposed to cAMP are skewed towards a regulatory activation status, thus 
suggesting that cAMP contributes to the attenuation of classical macrophage 
responses 7.  We also observed that cAMP inhibited nitrite production from 
classically activated macrophages to a similar extent as adenosine (Figure 6A).  
To investigate the role of A2aR-dependent signaling on NO production, we 
infected macrophages in the presence or absence of the A2aR-specific agonist, 
CGS21680.  CGS21680 inhibited nitrite production by infected IFNγ/LPS treated 
macrophages by 40-50% (Figure 6B).  We next addressed the functional 
consequence of A2aR stimulation during L.major infection in macrophages.  
Indeed, CGS21680 promoted the survival of intracellular parasites compared to 
infected IFNγ/LPS-treated macrophages cultured in the absence of adenosine or 
CGS21680 (Figure C,D).   Moreover, we saw that CGS21680 completely 
recapitulated results with adenosine with regard to both inhibition of NO and 
parasite survival (Figures 6B-D), thereby suggesting that the A2aR is the 
dominant adenosine receptor that inhibits nitric oxide production upon 
stimulation.  All together, we demonstrate that the A2aR is preferentially 
upregulated in macrophages during L.major infection and that the stimulation of 
the A2aR by low levels of ATP/adenosine inhibits the ability of macrophages to 
effectively clear Leishmania infection.   
 





Figure 6. A2aR signaling attenuates NO production in activated macrophages. (A) BMDMs 
were primed with IFNγ and stimulated with LPS in the absence or presence of 100µM adenosine 
or dbcAMP for 24 hrs.  Nitrite production was determined by Griess assay. The means +/- SD of 
triplicates are shown and are representative of 2 independent experiments. (B-D) BMDMs were 
infected with L.major in the absence (naïve) or presence of IFNγ/LPS +/- 100µM adenosine or 
10µM CGS21680.  48 hrs later, nitrite production (B) and parasite survival was quantified within 
100 BMDMs via fluorescence microscopy (C). The means +/- SD of triplicates are shown and are 
representative of 2 independent experiments.  Representative images are shown of parasites 
(green) within macrophages (blue)  (D). 
 




Leishmaniasis is a potentially life-threatening disease that is caused by 
parasites that preferentially infect tissue-resident macrophages. In 
immunocompetent humans and mice, the immune response eventually polarizes 
and a dominant cell-mediated response emerges to ultimately clear the infection. 
In contrast, susceptible individuals develop non-healing lesions at the site 
infection occur in response to the maintenance of Th2 conditions.  While it has 
been shown that IgG-opsonized parasites promote the Th2 environment to the 
detriment of the host via FcR ligation 8, 9, 39, it remains elusive what factors 
present in tissue early in infection render macrophage susceptible to parasites, 
regardless of the production of IFNγ.  Here, we reveal that extracellular ATP can 
inhibit NO production in classically activated macrophages via conversion to 
adenosine, which subsequently sustains survival of L.major parasites within 
macrophages.  Specifically, this study provides exciting new insight regarding the 
roles of the adenosine receptors on macrophages including 1) the A2aR is the 
major adenosine receptor responsible for the inhibition of nitric oxide in 
macrophages, 2) A2aR-dependent signaling promotes intracellular survival of 
pathogenic parasites and 3) L.major itself may specifically target the upregulation 
of the A2aR to evade innate host defenses. 
These results are consistent with reports indicating that excessive 
adenosine levels present in serum and tissue are a hallmark of individuals 
deficient in adenosine deaminase (ADA), which represents nearly 10% of total 
severe combined immunodeficiency disease (SCID) patients and are highly 
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susceptible to a variety of microbial infections 50.  In addition, it has been 
proposed that high extracellular adenosine concentrations present in newborn 
serum may play a role in the inefficient clearance of microbial infections in 
newborns and children, compared to adults 51. However, while it has been known 
that adenosine can interfere with host defenses, the specific contribution of each 
adenosine receptor has remained unknown.   
The A2Rs, A2aR and A2bR, exhibit great immunomodulatory activity and 
are the only adenosine receptors coupled to the Gαs subunit.  Much of their anti-
inflammatory activity is attributed to the induction of cAMP and blockade of NFκB 
pathways 116.  Although, the anti-inflammatory potential of adenosine via A2Rs is 
well documented, the role of adenosine-mediated signaling in regulating anti-
microbial responses remains elusive.  Recently, Alfonso and colleagues have 
demonstrated that administration of adenosine at the time of infection with 
Leishmania parasites decreases the size of the lesion at the site of infection in 
mice and that these results were reversed upon addition of the A2bR-specific 
antagonist, MRS1754 suggesting that A2bR signaling may be important for 
mediating the severity of the lesion 117. Importantly, the modulation in lesion size 
appears to be predominantly due to changes in the number of immune cells 
infiltrating to the site of infection.  However, it is important to note that 
administration of adenosine receptor antagonists in vivo will negatively affect 
adenosine receptors on every cell type and that the A2bR is expressed on 
immune cells and structural cells including smooth muscle cells and endothelial 
cells 74.   Indeed, A2bR-deficient mice exhibit decreased leukocyte migration on 
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account of increased integrin expression and binding 74.  Therefore, it will be 
important to develop macrophage-specific adenosine receptor-deficient mice to 
address the specific contribution of adenosine signaling on macrophages in vivo.  
Moreover, it was demonstrated that blockade of the A2bR improves polymicrobial 
sepsis survival in mice.  This effect was largely attributed enhancement of 
phagocytosis capacity, thus limiting the severity of bacteremia 95.  Although these 
results highlight a role for the A2bR in mediating phagocytosis and inflammatory 
cell recruitment, the study presented here is the first to identify a role for the 
A2aR in mediating host defense.  Moreover, our study indicates that pathogens 
may specifically target the upregulation of the A2aR as a virulence mechanism to 
evade macrophage killing.  However, it remains unclear how the expression of 
A2Rs is regulated, thus it will be interesting to further investigate the molecular 
mechanisms governing transcriptional induction of A2ar by L.major. 
Interestingly, a growing list of pathogens has been shown to modulate the 
host purinergic signaling system.  Myobacterium tuberculosis, for example, 
enhances ATP secretion from infected macrophages leading to the 
P2X7/NLRP3-inflammasome activation118.  While we did see a marginal 
improvement of NO production with the addition of rIL-1β to IFNγ treatment, 
compared to IFNγ treatment alone, we did not observe a significant increase in 
NO or decrease in L.major survival in the presence of LPS, suggesting that 
autocrine IL-1β signaling overlaps considerably with LPS-induced signaling.  This 
is likely due to common intracellular domains and association with MyD88.  
Importantly, the level of ATP required to elicit IL-1β release is relatively high and 
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under normal conditions, can only be achieved with >1mM eATP.  While such 
levels of eATP have yet to be discovered in vivo, it is estimated that 1-5mM ATP 
resides within healthy cells.  Thus, under pathological conditions in which cells 
lose their membrane integrity due to stress, damage, or death, intracellular stores 
of ATP can be released into the extracellular space.  As such, it is conceivable 
that this IL-1β-dependent control of parasites may be enlisted later in the disease 
when the infected tissue becomes necrotic.  Additionally, ATP release and IL-1β 
may further augment tissue destruction causing greater harm to the host.   
We recently discovered that TLR ligands induce the release of ATP from 
macrophages; however the level of ATP released under these conditions is 
relatively low (nano-micromolar range).  Subsequently, macrophages rapidly 
hydrolyze this self-derived eATP into adenosine, thus representing an 
autonomous regulatory mechanism to control TLR-induced inflammatory 
responses 54.  It will be interesting to assess whether L.major induce a similar 
mechanism upon infecting macrophages, whereby low levels of ATP are 
released to enhance their pathogenicity.  Indeed, Shigella flexneri has been 
shown to actively induce ATP release from host epithelial cells leading to 
increased dissemination 119 and recently low levels of ATP released form HIV-
infected cells was shown to be important in enhancing envelope fusion and viral 
entry into the targeted T cells 120.  Therefore, our data support the notion that 
host-derived eATP may be a virulence factor utilized by pathogens.  Collectively, 
the results from this study illustrate a novel A2aR-dependent mechanism 
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employed during L.major infection that suppresses macrophage anti-microbial 
responses (Figure 7).  
 
             
Figure 7. A model illustrating a novel A2aR-dependent immune evasion mechanism 
elicited by L.major. In response to IFNγ/LPS stimulation, macrophages exhibit a classical 
activation state hallmarked by the ability to produce high levels of nitric oxide. (1.) Thus, upon 
infection, classically activated macrophages readily kill intracellular pathogens such as L.major. 
(2.) However, extracellular ATP levels likely rise at the site of infection due to immune cell 
activation and stress. (3.) The results of this study reveal that while CD39 (red) and CD73 (black) 
activity are intact, macrophages upregulate the A2aR (blue) in response to infection. (4.) Upon 
A2aR stimulation, IFNγ/LPS-induced NO decreases likely through a cAMP-dependent pathway. 
Thus, in the presence of low levels of eATP/adenosine, classically activated macrophages are 
rendered susceptible to L.major infection. 
 
 122   
 
Chapter 5:  Conclusions and Final Thoughts 
 
In the clinic and in animal models of inflammatory and infectious diseases, 
the switch between macrophage activation states has been well documented.  
However, the signals that direct macrophage plasticity remained enigmatic.  The 
major discovery of the work presented here, is the identification and 
characterization of a complex macrophage-intrinsic regulatory mechanism that is 
initiated early in response to inflammatory stimuli and directs the transition to an 
anti-inflammatory, regulatory activation state.  These observations suggest that 
inflammatory macrophage activation is inherently transient and that a switch in 
macrophage activation states may be critical to maintaining homeostasis.  
Results collected throughout this study challenge our understanding of regulatory 
macrophage development and thus illustrates a new model of macrophage 
activation such that macrophages, themselves, are capable of controlling their 
own activation state.  They do so by releasing and converting ATP and by 
increasing adenosine (A2) receptor expression and sensitivity to newly generated 
adenosine within their local microenvironment.  
 * The novelty of the work presented in Chapter 2 was the demonstration 
that macrophages actively secrete low levels of ATP into their local extracellular 
environment upon sensing pathogen-associated molecules.  While, it has been 
known that unlike most mammalian cells, tissue macrophages are primarily 
dependent on glycolysis for cellular metabolism 65, we revealed for the first time 
that following toll-like receptor (TLR) ligation, macrophages actively release a 
                                            
* Paragraph adapted from: Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage 
inflammatory responses. J Leukoc Biol. Nov 2013;94(5):913-919. 11 
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fraction of glycolysis-generated ATP into the extracellular milieu via pannexin-1 
channels 121.  We then monitored the fate of macrophage-derived eATP and 
found that macrophages rapidly hydrolyze eATP by employing the ecto-
nucleoside triphosphate diphosphohydralse (ENTPDase1/CD39).  Within hours 
of stimulation, macrophages completely convert released eATP into adenosine.  
We further show that low (sub-millimolar) levels of eATP drive a switch in 
macrophage polarization from an inflammatory to a regulatory activation status.  
In the time it takes to generate, release, and hydrolyze ATP, TLR-activated 
macrophages are simultaneously undergoing a dramatic transcriptional 
reprogramming, culminating in the development of a regulatory activation status.  
CD39-mediated generation of adenosine from eATP was integral to this 
transition, as it is required to initiate the hydrolysis of eATP into eAMP, which 
then is selectively dephosphorylated by the ecto-AMPase, CD73 to yield 
adenosine.   
*  We then observed that adenosine, derived from eATP potently 
suppressed TNFα and IL-12 synthesis, while simultaneously enhancing the 
expression IL-10, the hallmark of regulatory macrophage activation.  Therefore, 
we also provided a detailed analysis of the genetic signature of ATP/adenosine-
treated macrophages.  Importantly, we observed that in addition to IL-10, ATP-
derived adenosine also upregulated an array of immunomodulatory molecules 
including heparin-binding epidermal growth factor (HB-EGF), sphingosine kinase 
(Sphk1), and IL-33 1, 6, 72.  Interestingly, no upregulation of Fizz1, Ym1, or 
                                            
* Paragraph adapted from: Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage 
inflammatory responses. J Leukoc Biol. Nov 2013;94(5):913-919. 11 
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Mannose Receptor was observed indicating that ATP/adenosine selectively 
promote the development of regulatory macrophages and are not representative 
of IL-4-induced alternatively activated macrophages (AAMs).  Arg1 was also 
upregulated on these macrophages.  Although, Arg1 has historically been 
thought of as a distinct AAM marker, it has recently been demonstrated that Arg1 
can be induced via IL-4/STAT6-independent mechanisms including via STAT3 98 
and GPCR/cAMP pathways 99, 100, thus indicating that Arg1 may not be a stable, 
reliable marker of AAMs, and thus may be expressed more broadly by 
macrophages.  The biomarker signature of TLR-stimulated macrophages in the 
presence of low levels of ATP/adenosine is therefore consistent with the 
phenotype associated with regulatory macrophages.   
* CD39 expressed on macrophages was integral in this reprogramming 
process, and macrophages from mice lacking CD39 were unable to transition to 
a regulatory phenotype. To demonstrate the biological relevance of these 
observations, we examined a mouse model of septic shock and demonstrated 
that the transfer of CD39-deficient macrophages into wild-type mice challenged 
with a sub-lethal dose of endotoxin conferred lethality (<25% survival).  This was 
in stark contrast to mice receiving wild-type (CD39+/+) macrophages, which 
largely survived (>75%) the challenge.  Furthermore, macrophages isolated from 
mice receiving wild-type macrophages exhibited elevated levels of IL-10, Arg1, 
HB-EGF, and IL-33 and low levels of TNFα and IL-12, whereas macrophages 
from mice that received CD39-deficient macrophages continued to exhibit an 
                                            
* Paragraph adapted from: Cohen HB, Mosser DM. Extrinsic and intrinsic control of macrophage 
inflammatory responses. J Leukoc Biol. Nov 2013;94(5):913-919. 11  
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inflammatory phenotype. This was the first study to specifically address the role 
of CD39 on macrophages in vivo.  This observation supports the theory that the 
development of regulatory macrophages is associated with increased survival of 
the host.  
We additionally extended these observations to human monocyte and 
macrophages.  Human blood-derived monocytes and monocyte-derived 
macrophages exhibited a similar regulatory profile in the presence of low levels 
of ATP/adenosine and also express high levels of CD39, suggesting that the 
natural ability to switch activation states in response to TLR activation is 
conserved among these species. Monocytes and macrophages play vital roles in 
the progression of inflammation and their inability to properly transition to a 
regulatory activation status to aid in the resolution of inflammatory responses 
often lead to severe tissue damage, organ failure and even death.  While, the 
literature regarding the role of CD39 in regulating inflammatory diseases such as 
diabetes, obesity, and cancer is growing122-125, the results presented here are the 
first to demonstrate the role of CD39 specifically on macrophages during 
inflammation. It will be important to develop macrophage-specific CD39-deficient 
mice to further interrogate the role of CD39 on macrophages during these 
diseases.  In addition, genome wide association studies (GWAS) within the 
human population should be performed to assess the potential correlation 
between CD39 and disease susceptibility or resistance.  Thus, results from this 
study emphasize the potential of macrophage-CD39 as a currently un-tapped 
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target for the development of more effective therapeutics for inflammatory 
disease.   
Throughout the course of this study, we also better characterized the 
mechanism by which ATP-derived adenosine promotes regulatory macrophage 
activation.  Interestingly, we observed that TLR-activated macrophages 
selectively increase their expression of the adenosine 2b receptor (A2bR).  Thus, 
these data indicate that upon activation, macrophages not only release and 
hydrolyze self-derived ATP, but also actively upregulate the A2bR to enhance 
their sensitivity to extracellular adenosine accumulating in their local extracellular 
environment.   We also reveal that in response to TLR activation, macrophages 
primarily employ the A2bR to self-regulate the production of inflammatory 
cytokines, thereby completing their CD39-initiated auto-regulatory circuit.  
Interestingly, in endothelial and aortic smooth muscle cells, CD39 and A2bR co-
associate with caveolae, suggesting that these molecules are strategically 
localized near each other on the surface of cells 126.  It will be interesting to 
examine whether this is true for macrophages, thus supporting the hypothesis 
that A2bRs reside in close proximity to CD39 to readily respond to newly 
generated macrophage-derived adenosine. Macrophages isolated from A2bR-
deficient mice expressed and secreted higher levels of TNFα and IL-12 
compared to their wild-type counterparts and exhibited substantial delays in the 
transition into a regulatory phenotype.   However, A2bR-deficient macrophages 
showed no defect in IL-10 production, thus indicating that the A2bR is not the 
major adenosine receptor mediating ATP/adenosine-induced IL-10.  Indeed, this 
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is consistent with previous work demonstrating that macrophages exposed to 
LPS or E.coli preferentially secrete IL-10 via an A2aR-dependent mechanism 96.  
Therefore, we identified a novel negative feedback mechanism controlling 
inflammatory cytokine production by macrophages that relies on the expression 
of the A2bR following TLR stimulation.  
 Functional plasticity is at the root of mounting an effective macrophage 
response to immunological threats without causing severe detriment to the host.  
While we showed that TLR activation normally results in a transient state of 
activation, IFNγ is a well-known sustainer of macrophage inflammatory 
responses, thus presenting us with a paradoxical situation: how can chronic 
inflammation persist in spite of self-limiting mechanisms that are mobilized to 
prevent overactive macrophage responses? In Chapter 3, we propose an 
underlying mechanism that may answer this question, wherein IFNγ blocks the 
induction of TLR-induced A2bR expression leading to the chronic production of 
high levels of TNFα and IL-12.   
 Similarly, it remains unknown the factors involved in regulating A2bR 
expression.  Our results show that naïve macrophages express low levels of the 
A2bR and that LPS-induced A2bR is temporally expressed, peaking at between 
2-8 hrs post stimulation.  Furthermore, the inhibition of A2bR expression by IFNγ 
persists throughout the exposure to LPS, indicating that IFNγ may interfere at the 
transcriptional level.  Future studies should be done to investigate whether IFNγ 
inhibits A2bR expression and signaling in human macrophages as well to 
establish that this phenomenon is central to the maintenance of hyperactive 
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macrophages across species.  It is important to note that although Hif1α has 
been shown to drive hypoxia-induced A2bR expression in human endothelial 
cells 110, our study indicates that it does not appear to be involved in mediating 
the induction of A2br by LPS in macrophages.  Thus, A2bR expression may be 
differentially regulated depending on the cell type and tissue environment.  We 
further showed Sp1 and CREB may have a role in regulating A2br levels.  These 
transcription factors have also been implicated in the regulation of other 
regulatory macrophage associated genes including IL-10 and HB-EGF 7, 109, 
therefore it is compelling to speculate that A2bR expression may be part of the 
regulatory macrophage gene signature and be used as a potential diagnostic tool 
to track the presence of macrophages transitioning into a regulatory activation 
state.  We are currently investigating the relevance of each of these binding sites 
in macrophage-A2bR expression upon TLR activation. It is tempting to assume 
that IFNγ prevents the induction of the A2bR by blocking the activation of an 
LPS-induced transcription factor responsible for increasing A2bR expression.  
However, IFNγ stimulation is a strong activator of STAT1, which itself can bind 
DNA and regulate transcription 26.  Indeed, we also discovered a putative GAS 
binding site, which can recruit STAT1, positioned between the Sp1 and CREB 
sites upstream of the A2br promoter.  Therefore, IFNγ-induced STAT1 may 
physically block the ability of LPS-induced transcription factors to bind DNA, 
thereby preventing the expression of the A2bR.  Alternatively, IFNγ may inhibit 
A2bR expression via post-transcriptional mechanism or epigenetic modifications.  
Because of the paucity of knowledge regarding the mechanism(s) by which the 
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A2bR is regulated, particularly in macrophages, these points will be important to 
address in order to improve our comprehensive understanding immune 
regulation. 
We also proposed the therapeutic application of engineered macrophages 
that over-express the A2bR as a potential treatment for chronic inflammatory 
diseases, in which high levels of IFNγ persist.  IFNγ intensifies macrophage 
inflammatory responses and is associated with the pathogenesis of chronic 
inflammatory bowel disease, lupus, and rheumatoid arthritis 25, 26.  It is important 
to re-iterate that although adenosine agonists may be viable treatment options, 
these molecules do not currently possess any specificity towards particular cell 
types.  Besides modulating inflammatory cytokine production, adenosine also 
affects the vasculature, muscle function and motor neuron activity.  Thus, for 
inflammatory diseases in which macrophages have a major role, it is imperative 
to develop adenosine-modulating therapies to specifically target macrophages in 
order to effectively resolve inflammation with minimal negative side effects.  Our 
preliminary studies highlighted in Chapter 3, reveal the ability to circumvent IFNγ-
induced hyper-inflammation by over-expressing the A2bR in macrophages.  In 
the future, it will be important to create macrophage cell lines, which stably 
express abundant A2bR levels and to test the efficacy for this treatment in in vivo 
models of chronic inflammatory disease.  It will also be important to assess 
whether immunomodulatory molecules such as IL-4, synergize with adenosine to 
promote severe immunosuppression or fibrosis.  
 IFNγ is also important for priming macrophages for effective host defense, 
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thus we were interested in investigating the consequence of extracellular ATP on 
adenosine signaling during infection.  To address this, we infected macrophages 
with Leishmania major, a virulent parasite that targets macrophages for their 
intracellular survival. The survival of L.major within macrophages is critically 
dependent on the presence of IFNγ, which drives the production of microbicidal 
NO.  Surprisingly, CD39 and CD73 activity appeared to remain unchanged 
during infection; however extracellular ATP/adenosine potently inhibited NO 
production and enhanced the survival of parasites despite the presence of IFNγ. 
While the A2bR expression remained lower in IFNγ primed macrophages 
compared to unprimed cells, which was consistent with our findings in chapter 3, 
the A2aR was the adenosine receptor most greatly upregulated in macrophages 
during L.major infection. Intriguingly, upregulation of the A2aR persisted in the 
presence of IFNγ, further corroborating our finding that IFNγ specifically interferes 
with A2bR expression. Subsequent use of A2aR-specific agonists demonstrated 
that A2aR signaling is the major adenosine receptor enabling the survival of 
parasites within activated macrophages.  The results from this study suggest that 
L. major may induce an increase in host A2aR expression as a virulence strategy 
to evade innate host defense mechanisms. However, it will be important to 
determine whether L.major is directly responsible for increasing A2aR levels.   
Currently, there is no cure for Leishmaniasis and few treatment options 
are available for the 1-2 million people infected annually 34.  Interestingly, infected 
individuals displaying non-healing lesions who do not receive antibiotic therapy, 
exhibit enhanced susceptibility to bacterial infections 127.  Thus, individuals 
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infected with Leishmania spp. are likely to be simultaneously exposed to 
pathogenic bacteria.  The most common treatment for Leishmaniasis is the 
administration of pentavalent antimonials, which is painful because they are 
injected directly into the lesion and also requires multiple doses with various 
dosing intervals.  More recent therapies have been made available such as 
SNAP cream (S-nitroso-N-acetylpenicillamine), which enhances NO production 
and is applied topically to the lesion as well as oral anti-fungal azoles that limit 
parasite growth 36. However, all existing treatments do not specifically target any 
particular cell type, and thus have multiple unfavorable side-effects including 
reactivation of latent viruses, enhanced susceptibility to bacterial infections, and 
even toxicity issues leading to pancreatitis or liver failure 127,128.  Thus, this study 
proposes that blocking A2aR-dependent signaling on macrophages may 
represent a novel way to more effectively therapeutically combat this infection.  
Perhaps one of the most unique findings was the apparent differential use 
of adenosine receptors by macrophages to mediate their diverse functional 
repertoire.  Throughout this study, we provided novel evidence that distinguishes 
these A2Rs on macrophages based on their induction of expression and the 
regulation of adenosine-mediated responses.  We report that TLR activation 
elicits the selective upregulation of the A2bR on macrophages, while L.major 
infection preferentially induces the A2aR.  Moreover, the A2bR is the primary 
adenosine receptor that inhibits TLR-induced TNFα and IL-12 production, while 
stimulation of the A2aR is the dominant adenosine receptor mediating NO 
attenuation and IL-10 production in macrophages.  It will be important to 
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delineate the molecular mechanisms regulating the differential expression and 
elucidate how these two closely related receptors can instill different outcomes 
upon activation. Importantly, IL-10 production remains intact even in the 
presence of IFNγ as well as in A2bR-deficient macrophages.  Thus, indicating 
that A2bR-mediated suppression of TNFα and IL-12 is independent of autocrine 
IL-10 signaling and that ATP/adenosine directly modulates macrophage 
activation.  
 The A2aR and A2bR (A2Rs) are GPCRs coupled to the Gαs subunit. Other 
ligands that stimulate GPCR-induced cAMP production such as prostaglandins, 
sphingosine phosphate, and C5a have also been shown to possess 
immunomodulatory behavior 116.  Previous work demonstrated that treating 
macrophages with cAMP could promote the development of regulatory 
macrophages via ERK activation 7. We also observed adenosine treatment 
prolongs LPS-induced ERK activation (data not shown) and therefore we 
hypothesize that adenosine signaling through the A2R may similarly influence 
macrophage physiology. A2aR and A2bR activation results in different 
downstream effects, however the molecular mechanisms governing this remain 
elusive.  One hypothesis is that GPCR-induced cAMP functions differently 
depending on the stimulus, thereby yielding various downstream effects.  
Additionally, it will be important to investigate whether over-expression of the 
A2bR can modulate anti-microbial activity or mask A2aR signaling.  Elucidating 
the molecular mechanism governing the differential effects mediated by 
adenosine will likely lead to the production of a novel class of therapeutics that 
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can substantially improve the way we treat inflammatory and infectious diseases.   
 A major hurdle of treating inflammatory diseases with inflammatory blockers 
(anti-TNFα for example) is that although they may effectively attenuate the 
inflammatory responses, they often significantly impair the ability to clear 
infections.   The results discussed in the work presented here, demonstrate that 
CD39 and A2Rs on macrophages represent unique targets to treat an array of 
ailments. For example, results from this work proposes the following scenarios in 
the future:  
•   Treating sepsis by modulating macrophage-CD39 activity according to the 
progression of the disease, whereby activating CD39 on macrophages 
during the initial phase of sepsis (SIRS) to prevent septic shock.  At later 
stages of the disease, a dampening CD39 activity once the inflammatory 
response subsides to prevent enhanced susceptibility to infection.  
Moreover, A2bR expression on macrophages could be used to monitor 
the transition of inflammatory to immunosuppressive macrophages in 
sepsis patients as a prognostic tool to better tailor their treatment. 
 
•   Managing rheumatoid arthritis by injecting A2bR-engineered macrophages 
into the inflamed joint, which will dampen the inflammation and aid in the 
resolution of the disease without negating innate anti-microbial activity, 
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 The culmination of this work is the identification and characterization of a 
novel autoregulatory mechanism governing inflammatory macrophage plasticity. 
Prior to these studies, eATP was predominantly regarded as a pro-inflammatory 
stimulus.  However, based on the work presented here we propose that eATP, 
derived from TLR-stimulated macrophages can be anti-inflammatory and drive 
the development of regulatory macrophages.  A major discovery presented 
throughout this thesis was that inflammatory macrophage activation is normally 
transient and that CD39-mediated regulation is critical in maintaining functional 
plasticity in macrophages.  Thus, this model proposes that the resolution of 
inflammation is actively induced and does not arise by passive exhaustion of the 
pro-inflammatory response or is merely quiescent.  Rather immunosuppressive 
macrophages actively participate in resolving inflammation and maintaining 
homeostatic tissue conditions.  This work further reveals that this complex auto-
regulatory mechanism can be dynamically altered during the course of a disease, 
thus re-directing the functional destiny of an activated macrophage to either 
become chronically inflammatory or severely susceptible to infection.  Results 
from the studies presented here offer many promising new targets and novel 
strategies that may improve the diagnosis and clinical outcome for myriad 
inflammatory and infectious diseases in which the switch from inflammatory to 
regulatory macrophages is important. 
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